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Abstract
Accurate diagnosis is often the first step towards the treatment and prevention of
disease. Many quantitative comparisons of diagnostic tests have relied on meta-analyses,
which are statistical methods to synthesize all available information in various clinical
studies. In addition, in order to effectively compare the growing number of diagnostic
tests for a specific disease, innovative and efficient statistical methods to simultaneously
compare multiple diagnostic tests are urgently needed for physicians and patients to
make better decisions.
In the literature of meta-analysis of diagnostic tests (MA-DT), discussions have been
focused on statistical models under two scenarios: (1) when the reference test can be
considered a gold standard, and (2) when the reference test cannot be considered a gold
standard. We present an overview of statistical methods for MA-DT in both scenarios.
This dissertation covers both conventional and advanced multivariate approaches for
the first scenario, and a latent class random effects model when the reference test itself
is imperfect.
As study design and populations vary, the definition of disease status or severity
could differ across studies. A trivariate generalized linear mixed model (TGLMM)
has been proposed to account for this situation; however, its application is limited to
cohort studies. In practice, meta-analytic data is often a mixture of cohort and case-
control studies. In addition, some diagnostic accuracy studies only select a subset of
samples to be verified by the reference test, which is known as potential source of partial
verification bias in single studies. The impact of this bias on a meta-analysis has not
been investigated. We propose a novel hybrid Bayesian hierarchical model to combine
cohort and case-control studies, and correct partial verification bias at the same time.
A recent paper proposed an intent-to-diagnose approach to handle non-evaluable in-
dex test results, and discussed several alternative approaches. However, no simulation
studies have been conducted to test the performance of the methods. We propose an
extended TGLMM to handle non-evaluable index test results, and examine the perfor-
mance of the intent-to-diagnose approach, the alternative approaches, and the proposed
approach by extensive simulation studies.
iii
To compare the accuracy of multiple tests in a single study, three designs are com-
monly used: 1) the multiple test comparison design; 2) the randomized design; and 3)
the non-comparative design. Existing MA-DT methods have been focused on evaluating
the performance of a single test by comparing it with a reference test. The increasing
number of available diagnostic instruments for a disease condition and the different
study designs being used have generated the need to develop an efficient and flexible
meta-analysis framework to combine all designs for simultaneous inference. We develop
a missing data framework and a Bayesian hierarchical model for network meta-analysis
of diagnostic tests (NMA-DT), and offer key advantages over traditional MA-DT meth-
ods.
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Chapter 1
Introduction
Accurate diagnosis of a disease is often the first step toward its treatment and preven-
tion. The performance of a binary test of interest (candidate or index test) is commonly
compared to a reference test (preferably a “gold standard” test), then measured by a
pair of indices such as sensitivity (Se) and specificity (Sp). Sensitivity is defined as the
probability of testing positive given a person is diseased, and specificity is defined as
the probability of testing negative given a person is disease-free[1]. For a toy example,
ultrasound is the candidate or index test in diagnosing rotator cuff tears, and the gold
standard test is arthroscopic surgery. In one study, to estimate the Se and Sp of ultra-
sound, a group of participants are tested by both ultrasound and the gold standard, and
test outcomes are compared in a cross-tabulated 2 × 2 table (Table 1.1). In this study,
Se is estimated as Pr(Ultrasound = +|Diseased) = 80/100 = 0.8 and Sp is estimated
as Pr(Ultrasound = −|Non-diseased) = 180/200 = 0.9. Other frequently used indices
include positive and negative predictive values (PPV and NPV), and positive and neg-
ative diagnostic likelihood ratios (LR+ and LR−). PPV is defined as the probability
of being diseased given a positive index test result, and NPV is defined as the proba-
bility of being disease-free given a negative index test result. In this example, PPV is
estimated as Pr(Diseased|Ultrasound = +) = 80/100 = 0.8 and NPV is estimated as
Pr(Non-diseased|Ultrasound = −) = 180/200 = 0.9.
The growing number of assessment instruments, as well as a rapid escalation in trial
costs, has generated an increasing need for scientifically rigorous comparisons of the di-
agnostic tests in clinical practice. Meta-analysis of diagnostic test (MA-DT) is a useful
1
2Table 1.1: 2 × 2 table for a toy example
Arthroscopic
Ultrasound + (Diseased) − (Non-diseased) Total
+ 80 20 100
− 20 180 200
Total 100 200 300
tool to combine evidence on diagnostic accuracies from multiple studies. Compared to
conventional meta-analyses of controlled clinical trials, it has several additional statis-
tical challenges that have been extensively studied in the literature, such as correlation
between test accuracy indices and heterogeneity of test performance across studies.
Other important topics in MA-DT, such as partial verification and mixture of study
designs remain challenging.
The increasing number of available diagnostic instruments for a disease condition
has generated a need to develop an efficient and flexible meta-analysis framework for
simultaneous inference. As a result, in order to effectively compare multiple diagnostic
tests, extending MA-DT from studying the performance of a single test, to enabling
simultaneous comparison of multiple test performance by a framework of network meta-
analysis of diagnostic tests (NMA-DT), is urgently needed for physicians and patients
to make better decisions in selecting tests.
1.1 Current development and challenges in meta-analysis
of diagnostic tests (MA-DT)
1.1.1 Literature review in MA-DT
In MA-DT, there is a great potential for heterogeneity due to differences in such
things as disease prevalence, study population characteristics, laboratory methods, and
study designs. While some study level covariates such as the mean age may explain
some of the variability, random effects models are commonly recommended to account
for other unobserved sources of variation. When a reference test can be considered
as a gold standard, several meta-analysis methods are available to account for this
3heterogeneity[2, 3, 4, 5, 6, 7, 8, 9, 10, 11]. Specifically, random effects models, including
the hierarchical summary receiver operating characteristic model [2] and bivariate ran-
dom effects meta-analysis on sensitivities and specificities[4, 10, 11], which are identical
in some situations, have been recommended [5, 8, 12]. Indeed, extensive examples and
simulations demonstrated that bivariate random-effects meta-analysis offers numerous
advantages over separate univariate meta-analysis [13, 14]. In general, generalized linear
mixed models (GLMM), which use the exact binomial likelihood, often perform better
than the linear mixed models which use a normal approximation[10, 15]. In addition, a
trivariate GLMM (TGLMM) was also proposed to jointly model the disease prevalence,
sensitivities and specificities[16].
In practice, disease status is often measured by a reference test that is subject to
nontrivial measurement error. This leads to a setting “without a gold standard”. When
the reference test is subject to measurement error, the evaluation of diagnostic tests in
a meta-analysis setting becomes more challenging. Only a few articles have described
meta-analysis models for diagnostic tests in the absence of a gold standard. Walter
et al.[17] discussed a latent class model for a meta-analysis of two diagnostic tests
assuming varying prevalence, but constant sensitivity and specificity across studies. A
more general latent class random effects model by Chu et al.[18] assumes sensitivity
and specificity of both tests as well as prevalence to be random effects. Sadatsafavi et
al.[19] presented a model where conditional dependence between tests is allowed but
other than prevalence, only one of the sensitivity or specificity can be implemented as
random effects. Dendukuri et al.[20] presented a Bayesian meta-analysis for the accuracy
of a test for tuberculous pleuritis in the absence of a gold standard. In this thesis, we
will perform a systematic review and comparison of the above mentioned methods.
1.1.2 Mixture of case-control and cohort studies
As introduced in the last section, the paired indices measuring diagnostic test perfor-
mance are potentially correlated and heterogeneous across studies, such that bivariate
random effects models on sensitivities and specificities have been recommended to ac-
count for such correlation and heterogeneity [5, 10, 4]. In addition, because the clas-
sification of disease status is typically based on a continuum of measurable traits, and
such continuous traits not only determine disease prevalence, but also misclassification
4rates (subjects with true levels close to the cut-point are more likely to be misclassified),
sensitivities and specificities can be correlated with study prevalences [21]. TGLMMs on
prevalence, sensitivities and specificities were proposed to account for such correlations
[22]. However, many meta-analyses of diagnostic tests in practice contain both cohort
and case-control study designs [23]. Using cohort design, a study first tests participants
with the index test, and then confirms disease status with the gold standard[24]. In case-
control design studies, groups of patients with and without disease are identified before
performing the index test [25]. Thus, case-control studies cannot be used to estimate
disease prevalence, and direct application of the trivariate random effects models has
been restricted to a meta-analysis with cohort studies only. In such situations, ignoring
the information on prevalence to fit the bivariate random effects model [10, 4, 8, 11] on
Se and Sp, or excluding case-control studies to fit the trivariate random effects model
[22] on prevalence, can potentially lead to a substantial loss of information contained
in the data. For example, the former approach ignores disease prevalence information
and the correlations between disease prevalence Se and Sp, which can lead to incorrect
estimation of PPV and NPV.
1.1.3 Partial verification bias
Partial verification is a common and important potential source of bias that usually
arises when the selection of samples to be tested by a reference standard test is affected
by the results of a diagnostic test [26, 27]. As stated in the quality assessment tool for
diagnostic accuracy studies (QUADAS), partial verification bias occurs when not all of
the study group receive confirmation of the diagnosis by the reference standard [28]. As
an illustration, let us use the previous example in Table 1.1 and assume that true Se
and Sp of ultrasound are 0.8 and 0.9, respectively and no sampling variation. However,
80% of the subjects with ultrasound positive outcomes are verified, while only 20% of
the subjects with ultrasound negative outcomes are verified by the gold standard. Let
ntd denote the number of subjects with test results T = t and disease status Dis = d
(t, d = 0, 1,m indicating negative, positive and missing results, respectively). We will
have n11 = 64, n01 = 4, n00 = 36, n10 = 16, n1m = 20 and n0m = 160. Now,
if we only use verified samples, we overestimate Se as Ŝe = n11/(n11 + n01) = 0.94
and underestimate Sp as Ŝp = n00/(n00 + n10) = 0.69. Moreover, the direction and
5magnitude of such bias depends on selection probabilities [29]. To avoid such bias,
ideally, all subjects should be verified. However, due to some practical issues such as
ethical and economic considerations, partial verification is ubiquitous. In a systematic
review of bias and variation in meta-analysis of diagnostic accuracy studies, 15 out of
31 (48%) meta-analyses contain at least one study with partial verification [29]. Thus,
it is important to adjust for partial verification bias in meta-analysis of diagnostic tests
[29, 30].
Methods to adjust for verification bias in a single study are widely published. Most
of the methods are built upon the missing at random (MAR) assumption, when the
decision to ascertain disease status only depends on the observed index test result,
T . Violations of this condition can happen when, for example, subjects with family
disease history are more likely to verify their desease status[1]. Begg and Greenes [31]
proposed a simple method based on Bayes theorem. Other methods such as multiple
imputation, direct maximum likelihood, or Bayesian approaches have been proposed
[32, 33, 34, 35, 36, 27]. These methods give unbiased estimates of Se and Sp for individual
studies, instead of recovering missing counts of subjects. Thus we would not be able
to apply the exact binomial likelihood assumption for a GLMM approach under meta-
analysis settings. Few sensitivity analysis methods are available under the assumption
of Missing Not At Random (MNAR), i.e., the probability of being verified by a reference
standard depends on the unobserved data[37, 38].
On the other hand, only limited papers are available on methods to adjust verifica-
tion bias in a meta-analysis setting. De Groot et al. [39] extended the Bayes theorem
method to adjusting for this bias in meta-analysis of diagnostic tests with nominal
outcomes. A two-stage Bayesian approach was described, where in the 1st stage the
probability distribution of the index test was calculated and in the 2nd stage PPV and
NPV are calculated using observed data based on their unbiasedness property under
the MAR assumption [1]. Bayes theorem is then applied to achieve pooled sensitivity
and specificity estimates. A few papers have discussed the missing data problem caused
by imperfect reference standards, but these papers are not aimed at partial verification
problems specifically. Previously introduced papers by Chu et al. [18] and Sdatsafavi
et al. [19] disscuss models for such a scenario.
61.1.4 Non-evaluable subjects
Most papers in the literature have discussed missing reference test outcomes (missing
disease status) and how to correct such bias, known as partial verification bias[31, 39,
34, 26]. However, index test outcomes can be non-evaluable as well, especially for tests
yielding dichotomous results, and different situations were discussed where index test
result can be non-evaluable: uninterpretable, intermediate and indeterminate [40, 41].
For a single study, there are many discussions about how to deal with non-evaluable
index test outcomes, such as excluding them [42], grouping them with positive or neg-
ative outcomes[42, 40], or using a 3 × 2 table to report them as an extension of the
standard 2× 2 table[42]. On the other hand, in meta-analysis, there is little discussion
of how to deal with missing index test outcomes[41]. The “classic” 2 × 2 table models
such as the bivariate linear mixed models[2, 11, 5, 43, 4, 8], bivariate GLMM[10, 44, 45]
and TGLMM [22] ignore missing index test outcomes. Recently, a paper by Schuetz et
al.[41] discussed this issue by studying different approaches dealing with index test non-
evaluable subjects. The paper conducted a meta-analysis of coronary CT angiography
studies and presented an intent-to-diagnose approach together with three commonly
applied alternative approaches. The intent-to-diagnose approach takes non-evaluable
diseased subjects as false positives and non-diseased subjects as false negatives such
that sensitivity and specificity won’t be overestimated. The other three alternative ap-
proaches in Schuetz et al.[41] are described in Chapter 4. The authors concluded that
excluding the index test non-evaluable subjects leads to over-estimation of sensitivity
and specificity and recommended the conservative intent-to-diagnose approach by treat-
ing non-evaluable diseased subjects as false negatives and non-evaluable non-diseased
subjects as false positives. However, no simulation studies have been conducted to
evaluate the performance of these approaches.
We can treat index test non-evaluable subjects as missing data. Schuetz et al.[41]
concluded that sensitivity and specificity could be over-estimated by excluding non-
evaluable subjects. In fact, under a reasonable general assumption, MAR, exclud-
ing non-evaluable subjects can provide unbiased estimates of them. A special case
of MAR is missing completely at random (MCAR), where missingness is indepen-
dent of both observed and unobserved variables [46]. Under MAR, T and M are
7independent given disease status Dis, where M = 1, 0 indicates missingness of in-
dex test outcome. Hence, excluding non-evaluable subjects will have unbiased esti-
mates of Se and Sp: Ŝe = Pr(T = 1|Dis = 1,M = 0) = Pr(T = 1|Dis = 1) and
Ŝp = Pr(T = 0|Dis = 0,M = 0) = Pr(T = 0|Dis = 0). Similarly, positive and neg-
ative likelihood ratios (LR+ and LR−) and area under the curve (AUC) estimates are
unbiased too. Under MCAR, Pr(M = 1|Dis = 1) = Pr(M = 1|Dis = 0), and hence
disease prevalence (pi) estimate is also unbiased if non-evaluable subjects are excluded.
However, when missing probabilities are not equal between diseased and non-diseased
participants, disease prevalence estimate can be biased if non-evaluable subjects are
excluded, leading overall estimates of PPV and NPV to be biased. PPV and NPV are
generally preferred by clinicians as measurements of how well a test predicts true disease
status because their interpretations are more intuitive: PPV is the probability that a
subject with positive intex test result is truly diseased and NPV is the probability that
a subject with negative intex test result is truly non-diseased[1]. However, none of the
approaches discussed in Schuetz et al. [41] can correct the bias in their estimates.
1.2 Network meta-analysis of diagnostic tests (NMA-DT)
As discussed, in the methodology literature of meta-analysis of diagnostic tests, a great
deal of attention has been devoted to developing methods to estimate the performance
of one candidate test compared to a reference test. However, in practice, it is becoming
common to compare multiple diagnostic tests in a meta-analysis, where studies may
compare different candidate tests and some studies may not include a gold standard
[47, 48, 19, 49, 50, 51]. As a consequence, existing meta-analysis methods reviewed
previously are not able to effectively analyze such data.
To compare the accuracy of multiple tests in a single study, three designs are com-
monly used [52]: 1) the multiple test comparison design where all subjects are diagnosed
by all candidate tests and verified by a gold standard; 2) the randomized design where
subjects are randomly assigned to one of the candidate tests, and all subjects are verified
by a gold standard; and 3) the non-comparative design where different sets of subjects
are used to compare a candidate test to a gold standard or to another candidate test.
In the first two types of designs, confounding can be avoided because the comparisons
8are made on the same population or randomly assigned sub-populations. However,
in practice, many studies adopt the non-comparative design. Systematic reviews and
meta-analysis methods have been developed as useful tools to improve the estimation
of diagnostic test accuracy by combining information from multiple studies [2, 11]. The
growing number of assessment instruments, as well as the rapid escalation in their cost,
have generated an increasing need for scientifically rigorous comparisons of multiple
diagnostic tests in clinical practice. Thus, a flexible meta-analysis framework is needed
to combine information from all three designs for effectively ranking all candidate tests.
Very few papers have discussed how to simultaneously compare multiple candidate
tests in meta-analysis [19, 51]. A naive procedure is to conduct separate MA-DT of
each candidate test then compare their summary estimates [53]. However, there are
some important drawbacks of this procedure. First, for studies that compared multiple
tests, the accuracy estimates of each candidate tests from separate MA-DT are typically
correlated. Ignoring such correlations can potentially lead to invalid inference. Secondly,
when a candidate test is compared to a non-gold standard reference test in some studies,
at least a second study comparing the same set of tests is needed to solve the non-
identifiability problem [18]. Thirdly, when candidate tests are evaluated one at a time,
the number of studies is typically small, which can potentially lead to issues of model
fitting [15, 44]. In addition, as the test performance is summarized using a different
study population, the candidate tests are not directly comparable without certain strong
assumptions, thus limiting the generalizability of results. At last, separate MA-DT
does not allow for “borrowing of information”, which can potentially lead to statistical
efficiency loss.
The remainder of this thesis is structured as follows. First, Chapter 2 provides a
comprehensive review of the pros and cons of existing statistical methods for MA-DT,
including models for settings with and without a gold-standard test. We go through
both traditional and advanced methods in detail, and make recommendations for their
application. Chapter 3 then proposes a hybrid GLMM to combine information from
cohort and case-control studies, and to correct partial verification bias in meta-analyses
of diagnostic tests simultaneously. We build this model under the assumption of a
gold standard reference test. Model properties are investigated via simulation studies
and model application is demonstrated by case studies. In Chapter 4, we discuss the
9situation with non-evaluable subjects. We extend the TGLMM approach[22] by treating
non-evaluable subjects as missing data to adjust for potential bias. By extending the
TGLMM to account for missing data, potential bias in disease prevalence estimate
can be adjusted, and thus, bias in PPV and NPV estimates can be avoided. We add
simulation studies to investigate and compare the extended TGLMM and alternative
methods discussed in Schuetz et al.[41]. Next, we extend our topic from MA-DT to
NMA-DT in Chapter 5, where we develop a NMA-DT framework from the perspective
of missing data analysis. By simultaneously comparing all candidate tests and the gold
standard, the proposed approach can make use of all available information, allow for
borrowing of information across studies and rank diagnostic tests through full posterior
inferences. Finally, Chapter 6 summarizes our findings, limitations, and discuss areas
for potential future work.
Chapter 2
Statistical methods for
multivariate MA-DT
In this chapter, we provide a comprehensive review of existing statistical methods for
MA-DT, including models for settings with and without a gold-standard test. Both
conventional and advanced models are illustrated and compared for their advantages
and disadvantages. In section 2.1, we summarize and compare different models when the
referent test can be considered as a gold standard. In section 2.2, we introduce models
in the absence of a gold standard. In section 2.3 we draw summaries of all methods and
give recommendations.
2.1 Statistical methods when the reference test is a gold
standard
When the reference test can be considered as a gold standard, let nitd denote the number
of subjects with index test results T = t and disease status Dis = d for study i (i =
1, 2, . . . , N), where t and d are defined in Chapter 1. Thus, ni11, ni00, ni01, and ni10 are
the number of true positives, true negatives, false positives and false negatives for the ith
study, respectively. Let ni1+ = ni11 + ni10 and ni0+ = ni01 + ni00 be the study-specific
numbers of diseased and disease-free subjects. Then the study-specific sensitivity and
specificity can be estimated as Ŝei = ni11/ni1+, and Ŝpi = ni00/ni0+. See Table 2.1 for
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Table 2.1: 2 by 2 table for ith study
Reference test
Index Test Positive (+) Negative (−) Total
Positive(+) ni11 nni01
Negative(−) ni10 ni00
Total ni1+ ni0+ ni++
a typical 2 by 2 table for study i.
In this section, we will first discuss the conventional summary receiver operating
characteristic (ROC) approach and a bivariate approach using linear mixed models
(LMM). Both methods require direct calculations of study-specific sensitivities and
specificities, and an ad hoc continuity correction when there are zero events in either
arm of a study. Second, we will discuss the hierarchical summary ROC approach for
jointly modeling positivity criteria and accuracy parameters, and a bivariate approach
using GLMM for jointly modeling sensitivities and specificities. At last, we will discuss
a trivariate approach using GLMM for jointly modeling prevalence, sensitivities and
specificities to assess the correlations among the three parameters. The hierarchical
summary ROC approach, and the bivariate and trivariate approaches are based on the
exact binomial distribution and thus do not require any ad hoc continuity correction.
[43]
2.1.1 The summary ROC method
The summary ROC curve method was first proposed by Moses et al. [54]. Reflecting the
trade-off between sensitivity and specificity caused by implicit thresholds, this method
has been widely used in diagnostic tests studies. The observed Se and Sp estimates
form a concave ROC curve shape as the threshold varies. Such curve can be fitted by
back-transforming the linear relationship between logit transformations of Se and Sp to
the ROC space: First, if some studies have ni11 = 0 or ni00 = 0, an ad hoc continuity
correction is applied by adding 0.5 to each of the 4 cells of such studies. After the
correction, sensitivity is estimated to be Ŝei = (ni11 + 0.5)/(ni1+ + 1) and specificity is
estimated to be Ŝpi = (ni00 + 0.5)/(ni0+ + 1) for the ith study. Second, define variables
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S and D as the sum and the difference of logit transformed sensitivity and specificity,
such that Si = logit(Ŝei) + logit(Ŝpi) and Di = logit(Ŝei)− logit(Ŝpi), where logit(p) =
log{p/(1 − p)}, 0 < p < 1. (This notation is slightly different than Moses et al.[54]
because the original transformation is on Se and false positive rate (FPR, equivalent to
1-Sp)). One can see that Si = log(ÔRi), where ÔRi =
ni11
ni10
/
ni01
ni00
is the diagnostic odds
ratio for the ith study. Third, for N studies, fit a linear regression line S = a + bD
either by an ordinary least squares or by a weighted least squares method weighing by
the inverse of within-study variances var(log(ORi))
−1, where var(log(ORi)) = 1/ni11 +
1/ni10 + 1/ni01 + 1/ni00 [4]. After fitting the regression line using either method, one
can plot the summary ROC curve by the two estimated coefficients (i.e., intercept aˆ
and slope bˆ),
Se = {1 + e−aˆ/(1−bˆ) × (Sp/(1− Sp))(1+bˆ)/(1−bˆ)}−1, (2.1)
with Se on the y-axis and 1 − Sp on the x-axis. To adjust for study-level covariates
Z (e.g., different sites the diagnostic tests were taken), one can fit a model with Si =
a+ bDi + cZi. We can then have Si = aˆ+ bˆDi + cˆZi = (aˆ+ cˆZi) + bˆDi = aˆ
′+ bˆ′Di. The
summary ROC curve can be plotted according to new estimates aˆ′ and bˆ′ given Z.
The summary ROC method is easy to perform but suffers some shortcomings. On
the one hand, its interpretations are known to be problematic. Walter discussed the in-
terpretation of area under the curve (AUC) [17]. A summary ROC curve located closer
to the left upper corner of the ROC space will have a larger AUC, indicating better
predictive accuracy of a test [17]. However, the conclusion becomes unreliable when
comparing tests whose summary ROC curves may cross each other. Alternative statis-
tics, such as the partial AUC [55] and the Q point [56] also have limited applications. On
the other hand, the model setting has some drawbacks. First, because Si = log(ÔRi),
the data are reduced to one outcome measure per study: diagnostic odds ratio. In-
dependent summaries of sensitivity and specificity are not available, which could be
important in test evaluating. Second, the model is restricted in that the between-study
heterogeneity can only be adjusted by study level covariates, such that some compo-
nents of the variance might not be explained. This is the reason why both Moses et
al.[54] and Irwig et al. [57] recommended the unweighted least squares rather than the
weighted as in a fixed effect model as a few large studies may dominate the result if
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the between-study variation is present. Third, in practice, study characteristics besides
the cut-point effect contribute to the trade-off between sensitivity and specificity within
a study[54, 58], which are not incorporated in the summary ROC curves. Finally, an
arbitrary continuity correction is needed to handle zero cells. Moses showed that it can
push the summary ROC curve far from the ideal upper left corner of the ROC space,
giving biased results [55].
2.1.2 A bivariate approach based on LMM
To improve over the summary ROC method, Reitsma et al. proposed a bivariate LMM
[11]. The model proceeds as follows. First, a logit transform of the sensitivity and
specificity is applied to each study. Different from the summary ROC method, they
are considered as random by allowing variation according to normal distributions, that
is logit(Sei) ∼ N(α, σ2µ) and logit(Spi) ∼ N(β, σ2ν) . A bivariate normal distribu-
tion can include possible correlation between sensitivity and specificity within study:(
logit(Sei)
logit(Spi)
)
∼ N
((
α
β
)
,Σ
)
, where Σ =
(
σ2µ σµν
σµν σ
2
ν
)
and σµν denotes the
covariance between logit sensitivity and specificity.
Second, to account for the sampling variation, the estimated logit sensitivity and
specificity are assumed to be normally distributed as
(
logit(Ŝei)
logit(Ŝpi)
)
∼ N
((
logit(Sei)
logit(Spi)
)
, Ci
)
for study i, with Ci =
(
var(logit(Ŝei)) 0
0 var(logit(Ŝpi))
)
, var(logit(Ŝei)) = 1/ni11 +
1/ni10 and var(logit(Ŝpi)) = 1/ni10 + 1/ni00. Note that, the general rule that ni1+Ŝei,
ni1+(1 − Ŝei), ni0+Ŝpi and ni0+(1 − Ŝpi) are at least five need to hold for normal ap-
proximation to be valid. Consequently, logit(Ŝei) and logit(Ŝpi) are assumed to have
the following bivariate normal distribution:(
logit(Ŝei)
logit(Ŝpi)
)
∼ N
((
α
β
)
,Σ + Ci
)
(2.2)
Because the distributions of sensitivity and specificity are often skewed, one may prefer
inference based on the medians rather than means as the overall diagnostic test perfor-
mance summary. Based on parameter estimates, the median sensitivity and specificity
can be back-transformed as ŜeM = logit
−1(α̂) and ŜpM = logit−1(β̂), where logit−1(·) is
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the inverse logit function such that logit−1(x) = 1/(1 + exp(−x)). Similarly, confidence
intervals for ŜeM and ŜpM can be transformed from the confidence intervals of αˆ and β̂.
The correlation between sensitivity and specificity can be estimated as
σˆµν
σˆµ×σˆν . The stan-
dard errors are SE(ŜeM ) =
SE(α)
1/ŜeM+1/(1−ŜeM )
and SE(ŜpM ) =
SE(β)
1/ŜpM+1/(1−ŜpM )
based
on the Delta method. A summary ROC curve can be constructed by the regression of
logit sensitivity over given specificity as
logit(Se) = αˆ+
σˆµν
σˆ2ν
(
logit(Sp)− βˆ
)
. (2.3)
In general, this approach is superior to the summary ROC model by analyzing
sensitivity and specificity jointly in a bivariate LMM (BLMM). However, the bivariate
approach estimates the degree of correlation between sensitivity and specificity, as well as
both within- and between-study variation in the two indicators separately. A drawback
of this approach is that an ad hoc continuity correction is required in the presence of
zero cells, as with the summary ROC approach. In addition, the general rule of normal
approximation is sometimes violated in practice[10]. The bivariate model can adjust for
covariates by regression model in the mean vector of the bivariate normal distribution:(
logit(Sei)
logit(Spi)
)
∼ N
((
α+ γZi
β + λZi
)
,Σ
)
, where Zi is the study-level covariate and γ,
λ are the corresponding coefficient parameters [4].
2.1.3 The hierarchical summary ROC approach
Rutter and Gatsonis proposed a hierarchical summary ROC approach[2], which is a
simplification of the ordinal regression model by Tosteson and Begg: g(γj(x)) = (θj −
α′x)eβ
′x, where g(·) is a link function, γj(x) is the probability of a response being in one
of the ordered categories given covariates x, θj is the cutoff values of each category, α
is the location parameters and β is the scale parameter[59]. The hierarchical summary
ROC approach reduces the ordinal regression model to two categories (j = 1, 2), x
indicates true disease status (coded as 0.5 for Dis = 1 and −0.5 for Dis = 0) and γj(x)
correspond to positive test rates: Sei and 1− Spi (FPR)[2].
The first stage assumes binomial distributions of the number of positive outcomes
in the ith study, i.e., ni11 ∼ Bin(ni1+, Sei) and ni01 ∼ Bin(ni0+, 1 − Spi). Choose g(·)
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to be logit link, the model is written as
logit(Sei) = (θi + 0.5αi)e
−0.5β, logit(1− Spi) = (θi − 0.5αi)e0.5β, (2.4)
where the latter is the same as logit(Spi) = −(θi−0.5αi)e0.5β. The positivity criteria θi
model the tradeoff between sensitivity and specificity in each study. Direct interpreta-
tions of the accuracy parameters αi are that when β = 0, αi = logit(Sei) + logit(Spi) =
log(ORi), which is independent of θi. In the second stage, Rutter and Gatsonis allow θi
and αi to vary across studies[2]. Thus, θi and αi are assumed independently normally
distributed as:
(
θi
αi
)
∼ N
((
θ0
α0
)
,
(
σ2θ 0
0 σ2α
))
.
A summary ROC curve can be derived based on solving functions in (2.4) as
logit(Sei) = αie
−β/2 + e−βlogit(1− Spi)
Another possible construction of summary ROC curve pointed out by Chu et al.[12] is
based on the bivariate normal distribution of θi and αi and the Delta method as
logit(Se) = e−0.5βˆ(0.5αˆ0+θˆ0)+
0.25σˆ2α − σˆ2θ
0.25σˆ2α + σˆ
2
θ
×e−βˆ{logit(Sp)−e−0.5βˆ(0.5αˆ0−θˆ0)}. (2.5)
In addition, Arends et al. discussed several choices of SROC curves[9]. Median sen-
sitivity and specificity estimates are ŜeM =
{
1 + exp{−(θˆ0 + 0.5αˆ)e−0.5βˆ}
}−1
and
ŜpM =
{
1 + exp{(θˆ0 − 0.5αˆ)e0.5βˆ}
}−1
. Also, similar as the previous model, the hier-
archical summary ROC approach can incorporate study level covariates by
(
θi
αi
)
∼
N
((
θ0 + γZi
α0 + λZi
)
,
(
σ2θ 0
0 σ2α
))
.
The hierarchical summary ROC approach incorporates both within- and between-
study variability and the correlation between the summary statistics by random effects
θi and αi. Because sparse data is common in meta-analysis of diagnostic tests, espe-
cially under low event rates, an important advantage over the previous models is that
the hierarchical summary ROC approach avoids the continuity correction by assuming
binomial distributions[2]. A practical limitation of this model is that originally it is
fitted via Bayesian Markov Chain Monte Carlo approach using BUGS, which requires
some level of programming skills. This approach is found to be the same as the following
bivariate GLMM with alternative parameterizations in some situations.
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2.1.4 The bivariate generalized linear mixed model (GLMM)
Chu and Cole presented a bivariate GLMM to jointly analyze sensitivity and specificity
using logit link[10]. Later, the bivariate GLMM was adjusted to a general link function
[45]. The model starts with binomial distribution assumptions and applies link functions
on the probability parameters:
ni11 ∼ Bin(ni1+, Sei), ni00 ∼ Bin(ni0+, Spi), g(Sei) = α+ µi, g(Spi) = β + νi, (2.6)
where µi and νi are random effects follow bivariate normal distribution(
µi
νi
)
∼ N
((
0
0
)
,
(
σ2µ ρµνσµσν
ρµνσµσν σ
2
ν
))
, and g(·) is a link function such
as the logit, probit, and complimentary log-log link. Different link functions can be
applied to sensitivity and specificity separately. Though logit link is widely used in
meta-analysis to date, Chu et al. argued that, for some meta-analyses, the choice of
the link may affect model fit and inference[45]. The parameters σ2µ and σ
2
ν estimate the
between-study variances and ρµν explain possible correlations.
The model gives median estimates as ŜeM = logit
−1(αˆ) and ŜpM = logit−1(βˆ).
Similarly, confidence intervals for ŜeM and ŜpM can be transformed from the confidence
intervals of αˆ and βˆ. Study-level covariate Z can be adjusted by g(Sei) = α+ µi + γZi
and g(Spi) = β+νi+λZi, where γ, λ are corresponding coefficient parameters. Different
covariates could be adjusted for sensitivity and specificity. A regression line of g(Se) on
g(Sp), g(Se) = αˆ+ ρˆµν
σˆµ
σˆν
[g(Sp)− βˆ], gives the summary ROC curve by transforming to
the ROC space. Also, alternative choices of the regression lines can construct different
summary ROC curves with corresponding interpretations[9].
In addition to estimating the heterogeneity and correlation parameters, both hi-
erarchical summary ROC and bivariate GLMM approaches have advantages over the
bivariate LMM. First, the bivariate GLMM does not require the general rule of nor-
mal approximation to estimate var(logit(Ŝei)) and var(logit(Ŝpi)). Second, neither the
two approaches require continuity correction because direct calculation of study-specific
sensitivities and specificities is not involved. In the absence of study-level covariates,
the two approaches are the same model with alternative parameterizations[5].
Both hierarchical summary ROC and bivariate GLMM can be fitted using the max-
imum likelihood approach. Several numerical methods might be used, for instance,
17
the dual quasi-Newton optimization techniques, as implemented in SAS NLMIXED
procedure. The standard errors and confidence intervals for interested parameters are
estimated by the Delta method and are reported if specified in the ESTIMATE state-
ment. To restrict the correlation coefficient ρµν in the range [-1, 1] in the bivariate
GLMM, one can use the Fisher’s z transformation of ρµν in programming. AUC for
both hierarchical summary ROC and bivariate GLMM can be computed by numerical
integration implemented in SAS macro.
2.1.5 The trivariate GLMM
The above approaches involving only sensitivities and specificities work best if all or the
majority of the studies use case-control designs with non-identifiable prevalence. When
disease prevalence estimation is allowed in cohort study designs, we can derive other
clinically interested indices such as positive and negative predictive values (PPV and
NPV) by estimates of sensitivity, specificity and prevalence. In this case, a challenge
is the potential dependence of test performance on prevalence, which can be termed
spectrum bias[26]. Typically, such dependence is mostly concerned when the bivariate
diagnostic outcome is based on the cut point on continuous traits, thus misclassification
rates could be higher among subjects with true value around the cut point[60]. To
account for this potential dependence, Chu et al. extended the bivariate GLMM to a
trivariate GLMM jointly modeling the disease prevalence, sensitivity and specificity[16].
Recently, Li and Fine proposed a Pearson type correlation coefficient to assess this
dependence by an estimating equation-based regression framework[61].
Here, we only consider a trivariate GLMM based on the parameterization of pii, Sei
and Spi, where pii is the disease prevalence in ith study. The first level of this model
assumes binomial distributions:
ni1+ ∼ Bin(ni++, pii), ni11 ∼ Bin(ni1+, Sei), ni00 ∼ Bin(ni0+, Spi). (2.7)
The parameters are modeled via link functions: g(pii) = η + εi, g(Sei) = α + µi and
g(Spi) = β + νi. See Table 2.2 a two by two table accounting for disease prevalence.
To consider heterogeneity and potential correlations of the three parameters, εi, µi
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Table 2.2: 2 by 2 table for ith study accounting for prevalence
Reference test
Index Test Positive (+) Negative (−) Total
ni11 nni01
Positive(+) piiSei (1− pii)(1− Spi)
ni10 ni00
Negative(−) pii(1− Sei) (1− pii)Spi
ni1+ ni0+ ni++
Total pii 1− pii 1
and νi are assumed to be random effects with trivariate normal distribution:
εi
µi
νi
 ∼ N


0
0
0
 ,Σ
 , where Σ =

σ2ε ρεµσµσε ρενσνσε
σ2µ ρµνσµσν
σ2ν

The parameters σ2ε , σ
2
µ and σ
2
ν capture the between-study variance of the disease
prevalence, sensitivity and specificity while ρεµ, ρεν and ρµν represent correlations.
Standard software such as SAS NLMIXED can maximize the likelihood. To avoid
including unnecessary parameters, model selection criteria such as Akaike information
criterion (AIC) can be used. By parameter estimates, the medians are derived as piM =
g−1(ηˆ), ŜeM = g−1(αˆ) and ŜpM = g−1(βˆ). In this model, covariates can be incorporated
in sensitivities, specificities and disease prevalence as was done for the bivariate GLMM.
2.2 Statistical methods when the reference test is not a
gold standard
Limited meta-analysis tools are available when the reference test is imperfect. Walter
et al. discussed the latent class model for a meta-analysis of two diagnostic tests[17].
Sadatsafavi et al. presented a latent class random effects model[19]. However, other
than prevalence, only one of the sensitivity and specificity can be implemented as a
random effect. Dendukuri et al. presented a Bayesian approach, which is an extension
of the hierarchical summary ROC model, to adjust for different reference standards[20].
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We hereby introduce the latent class random effects model by Chu et al. using random
effects to allow variation and correlation in sensitivity, specificity and prevalence between
studies[18].
Let (SeBi, SpBi) be the pair of diagnostic accuracy parameters for the reference test
while (SeAi, SpAi) be the pair for the index test. To construct the 2 by 2 table (Table
2.3) for such studies, both the above pairs of statistics and the disease prevalence are
needed.
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Table 2.3: 2 by 2 table when the reference test is not a gold standard
Reference test
Index Test Positive (+) Negative (−) Total
ni11 ni01
Positive(+) pi11 = piiSeAiSeBi + (1− pii)(1− SpAi)(1− SpBi) pi01 = piiSeAi(1− SeBi) + (1− pii)(1− SpAi)SpBi
ni10 ni00
Negative(−) pi10 = pii(1− SeAi)SeBi + (1− pii)SpAi(1− SpBi) pi00 = pii(1− SeAi)(1− SeBi) + (1− pii)SpAiSpBi
ni1+ ni0+ ni++
Total pi1+ = piiSeBi + (1− pii)(1− SpBi) pi0+ = pii(1− SeBi) + (1− pii)SpBi 1
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The four counts in Table 2.3 follow a multinomial distribution, with log-likelihood
being:
logL =
∑
i
{ni11log(pi11) + ni10log(pi10) + ni01log(pi01) + ni00log(pi00)}. (2.8)
Chu et al. used random effects to model between and with-in study heterogeneity
and potential correlations[18]. We write this model in a form suit for a general link
function g():
g(pii) = η + εi; g(SeAi) = αA + µAi; g(SpAi) = βA + νAi;
g(SeBi) = αB + µBi; g(SpBi) = βB + νBi
where random effects follow a multivariate normal distribution: (εi, µAi, νAi, µBi, νBi)
′ ∼
N(0,Σ) with variance-covariance matrix
Σ =

σ2ε ρεµAσεσµA ρενAσεσνA ρεµBσεσµB ρενBσεσνB
σ2µA ρµAνAσµAσνA ρµAµBσµAσµB ρµAνBσµAσνB
σ2νA ρνAµBσνAσµB ρνAνBσνAσνB
σ2µB ρµBνBσµBσνB
σ2νB

Median estimates of prevalence, sensitivities and specificities can be achieved by
piM = g
−1(η̂), ŜeAM = g−1(α̂A), ŜpAM = g−1(β̂A), ŜeBM = g−1(α̂B) and ŜpBM =
g−1(β̂B). Variance and correlation parameter estimates can be derived from Σ̂. Co-
variates Z can be adjusted by linear regressions in the mean vectors, for instance
g(pii) = η + εi + γZi.
This latent class random effects model fills in the gap of models for meta-analysis of
diagnostic test under imperfect reference test condition. It can evaluate the performance
of both the diagnostic test of interest and the reference test while keep all the advantages
of the GLMMs. A limitation applies when fitting this model by SAS NLMIXED. One
could encounter convergence problem because of limited number of studies and relatively
large number of parameters. Possible simplifying assumption could be independence of
disease prevalence against the other parameters. Also, to avoid including redundant
random effects whose variance approximates zero, one can apply a forward selection
based on AIC.
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2.3 Discussion
In this chapter, we discussed the methods for evaluating the performance of diagnostic
tests for situations when the reference test can be considered a gold standard, as well as
situations when it is error-prone. Under the scenario with gold standard, we reviewed the
traditional summary ROC method, bivariate LMM and the hierarchical summary ROC
model. Then we focused on the random effect GLMM, because it has several advantages
over simpler methods. In this section, we showed how the bivariate GLMM can be
fitted using different link functions other than logit link, and extended the approach
to a trivariate GLMM to model prevalence as well as sensitivity and specificity. Under
the situation with no gold standard, we built upon the latent class model proposed by
Walter et al.[17] by adding random effects to quantify possible correlation and variation
following the method by Chu et al.[18].
Among the models presented, the summary ROC approach is simple and widely used,
while receives a number of critical comments on problems related to the interpretation
of summary ROC curves, the fixed effects model and the continuity correction. The
bivariate LMM improves over the summary ROC approach by assuming random effects
to explain both within- and between study variations and possible correlation. The
bivariate LMM can give inferences both in terms of summary ROC curves and summary
statistics of overall test performance. However, it has some limitations due to the
continuity correction and the validity of normal approximation. The GLMMs do not
have the limitations of the above models by assuming exact binomial distributions. The
bivariate GLMM, which is essentially the same as the hierarchical summary ROC model
in some situations, can be used when the majority of the studies use case-control designs
and the trivariate GLMM can be used when most of the studies are cohort studies.
A limitation related to the GLMMs is that the meta-analysis reported often includes
a mixture of case-control and cohort studies designs. Thus using either the bivariate or
the trivariate GLMM for all the studies can lead to some issues. Another problem arises
when fitting the trivariate GLMM and the latent class random effects models in SAS
procedure NLMIXED. The more random effects included, the longer it took to converge.
Under such situations, one can first get raw estimates of the desired parameters by fitting
the data in models with less random effects. The raw estimates can then be used to
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adjust the initial values to improve convergence. For the latent class random effects
model, one may need to apply simpler assumptions for ease of fitting.
Chapter 3
A hybrid Bayesian hierarchical
model combining cohort and
case-control studies for
meta-analysis of diagnostic tests:
Accounting for partial verification
bias
As discussed in the previous Chapter, many meta-analyses of diagnostic tests in practice
contain both cohort and case-control study designs [23]. However, the trivariate GLMM
[16] can only include cohort studies with information estimating study-specific disease
prevalence and the bivaraite GLMM cannot estimate prevalence and account for the
correlation between prevalence and accuracy parameters. On the other hand, some
diagnostic accuracy studies only select a subset of samples to be verified by the reference
test. It is known that ignoring unverified subjects may lead to partial verification bias
in the estimation of prevalence, sensitivities, and specificities in a single study [31].
However, the impact of this bias on a meta-analysis has not been investigated. In this
chapter, we propose a novel hybrid Bayesian hierarchical model combining cohort and
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casecontrol studies and correcting partial verification bias at the same time. We first
describe the proposed method in Section 3.1. We investigate the performance of the
proposed methods through a set of simulation studies in Section 3.2. Section 3.3 provides
two motivating case studies: assessing the diagnostic accuracy of gadolinium-enhanced
magnetic resonance imaging (MRI) in detecting lymph node metastases and of adrenal
fluorine-18 fluorodeoxyglucose positron emission tomography (PET) in characterizing
adrenal masses. This chapter ends with a discussion in Section 3.4. The data sets for
the two case studies are given in Appendix A.
3.1 Bayesian hierarchical model
3.1.1 Notations
Suppose that we have a meta-analysis with N diagnostic accuracy studies, and the
studies are indexed such that the N1 cohort studies come first, followed by N2 = N−N1
case-control studies. To allow partial verification in some of the first N1 cohort studies,
let nitd be the number of subjects with disease status Dis = d and test results T = t
(d, t = 0, 1,m indicating negative, positive and missing results, respectively) in the ith
study (i = 1, 2, . . . , N1) and pitd be the corresponding probability. As subjects with both
Dis and T missing do not provide any information, we will not consider them. Define pii,
Sei and Spi as in previous chapters. Let V = 1 and V = 0 denote the subject is verified
or not, respectively. Let ωitm (t = 0, 1) and ωimd (d = 0, 1) be the mutually exclusive
probabilities of missing for subjects with test result T = t and disease status Dis = d,
respectively. Furthermore, given the nature of case-control studies, it is unnecessary to
consider the influence of missing data in case-control studies: subjects with unverified
disease status generally do not exist and subjects with missing diagnostic test outcomes
can be ignored as prevalences in such studies are not well defined.
Table 3.1 presents the data structure and notation for the ith study when it is a
cohort study or a case-control study. In each cell, the number of cell counts and the
corresponding probabilities are presented. The left panel is for a cohort studies, which
extends a standard 2× 2 table (Table 2.2) to allow for partial verification. The sum of
all cell probabilities is one. The right half is for a case-control studies with a typical
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2 × 2 table (Table 2.1). The cell probabilities sum up to one for diseased and non-
diseased subjects separately. Derivations of the cell probabilities for cohort studies are
also provided at the footnote of Table 3.1 .
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Table 3.1: Data display for the ith study when it is a cohort study and when it is a case-control study.
Gold standard
Cohort (i = 1, . . . , N1) Case-control (i = N1 + 1, . . . , N)
Index test + − Missing + −
+ ni11 ni10 ni1m ni11 ni10
(1− ωi1m − ωim1)piiSei (1− ωi1m − ωim0)(1− pii)(1− Spi) ωi1m{piiSei + (1− pii)(1− Spi)} Sei 1− Spi
− ni01 ni00 ni0m ni01 ni00
(1− ωi0m − ωim1)pii(1− Sei) (1− ωi0m − ωim0)(1− pii)Spi ωi0m{pii(1− Sei) + (1− pii)Spi} 1− Sei Spi
Missing nim1 nim0
ωim1pii ωim0(1− pii)
In each cell, the number of cell counts are presented and the probabilities corresponding to the cell counts are
presented below the cell counts.
Probabilities for subjects with V = 1 in the ith cohort study:
pi11 = P (V = 1|Dis = 1, T = 1)P (Dis = 1)P (T = 1|Dis = 1) = (1− ωi1m − ωim1)piiSei,
pi10 = P (V = 1|Dis = 0, T = 1)P (Dis = 0)P (T = 1|Dis = 0) = (1− ωi1m − ωim1)(1− pii)(1− Spi),
pi01 = P (V = 1|Dis = 1, T = 0)P (Dis = 1)P (T = 0|Dis = 1) = (1− ωi0m − ωim1)pii(1− Sei),
pi00 = P (T = 0|Dis = 0)P (V = 1|Dis = 0, T = 0)P (Dis = 0) = (1− ωi0m − ωim0)(1− pii)Spi.
Probabilities for subjects with V = 0 in the ith cohort study:
pi1m = P (V = 0|T = 1)P (T = 1) = P (V = 0|T = 1){P (T = 1, Dis = 1) + P (T = 1, Dis = 0)} = P (V = 0|T =
1){P (Dis = 1)P (T = 1|Dis = 1) + P (Dis = 0)P (T = 1|Dis = 0)} = ωi1m{piiSei + (1− pii)(1− Spi)},
pi0m = P (V = 0|T = 0)P (T = 0) = P (V = 0|T = 0){P (T = 0, Dis = 1) + P (T = 0, Dis = 0)} = P (V = 0|T =
0){P (Dis = 1)P (T = 0|Dis = 1) + P (Dis = 0)P (T = 0|Dis = 0)} = ωi0m{pii(1− Sei) + (1− pii)Spi},
pim1 = P (V = 0|Dis = 1)P (Dis = 1) = ωim1pii, and pim0 = P (V = 0|Dis = 0)P (Dis = 0) = ωim0(1− pii).
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3.1.2 The likelihood with random effects accounting for heterogeneity
Let ω = {ωi} and θ = {θi}, where ωi = (ωi0m, ωi1m, ωim0, ωim1) and θi = (pii, Sei, Spi)
for study i. Assuming independence among subjects conditional on θi and ωi, the
likelihood is the product of contribution from each study. Multinomial likelihoods are
used for cohort studies and binomial likelihoods are used for case-control studies. In this
paper we assume verification is MAR, where the missing probabilities ω are independent
of prevalence and test accuracy parameters, θ. Therefore, the likelihood can be factored
as L(θ,ω|Data) ∝ L(θ|Data)× L(ω|Data). Specifically,
L(ω|Data) ∝
N1∏
i=1
ωni1mi1m ωnim1im1 ωnim0im0 ωni0mi0m ∏
j,k=0,1
(1− ωijm − ωimk)nijk
 (3.1)
and
L(θ|Data) ∝
N∏
i=1
Seni11i (1− Spi)ni10(1− Sei)ni01Spni00i
N1∏
i=1
pii
∑
j
nij1
(1− pii)
∑
j
nij0
hni1mi1 h
ni0m
i0 ,
(3.2)
where hi1 = piiSei + (1− pii)(1− Spi), hi0 = pii(1− Sei) + (1− pii)Spi and j = 0, 1,m.
To account for potential between-study heterogeneity, we consider a GLMM:
g(pii) = η + εi; g(Sei) = α+ µi; g(Spi) = β + νi, (3.3)
where g() is a link function, and (εi, µi, νi)
T is a random effect vector. To account for
potential correlation among pii, Sei and Spi, (εi, µi, νi)
T is assumed to be multivariate
normally distributed as (εi, µi, νi)
T ∼ N(0,Σ), where
Σ =

σ2ε ρεµσµσε ρενσνσε
σ2µ ρµνσνσµ
σ2ν
 .
The diagonal of the variance-covariance matrix Σ, (σ2ε , σ
2
µ, σ
2
ν), characterize the between-
study heterogeneity of disease prevalence, test sensitivities and specificities, while the
parameters (ρεµ, ρεν , ρµν) capture the correlations between the corresponding random ef-
fects (pii, Sei), (pii, Spi) and (Sei, Spi) in transformed scale, respectively. For simplicity,
we assume the same correlation structure for sensitivities, specificities and prevalences
for both case-control and cohort studies in this paper, which can be easily relaxed if
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necessary. However, for case-control studies, the study-specific prevalences are not con-
tained in the likelihood and not directly estimable, and can be predicted using this
correlation structure and study-specific sensitivity and specificity.
Study-level covariates, such as study quality, type of design (case-control versus
cohort studies), race distribution and mean age, can be incorporated through meta-
regression when necessary. For example, let g(pii) = η0 + η1Xi + εi, g(Sei) = α0 +
α1W i + µi and g(Spi) = β0 + β1Zi + νi, where Xi, W i and Zi denote the possibly
overlapping study-level covariate vectors. Note that the hybrid GLMM accounts for
different study designs in the construction of likelihood. Including type of study design
as a covariate is helpful when there is a systematic difference between cohort and case-
control studies, e. g., if the pooled sensitivity and specificity are believed to be different
between the two designs.
The marginal likelihood integrated over random effects is:
L(θ,ω) =
∫∫∫
L(θ,ω|Data)× p(µi, νi, εi|Σ) dεi dµi dνi (3.4)
Frequentist methods (such as the maximum likelihood estimate) may converge slowly
or have convergence problems due to the need to maximize the marginal likelihood with
trivariate integrations, and the corresponding asymptotic approximations for standard
errors of functions of parameters may not be sufficiently accurate [44].
3.1.3 Bayesian posterior sampling approach
In this chapter, we consider fully Bayesian approaches using Markov chain Monte Carlo
(MCMC) methods for parameter estimation. In most instances, inferences obtained
by Bayesian and classical frequentist methods are similar when the former uses non-
informative or weakly informative prior distributions for all model parameters [62].
Compared to the frequentist methods, MCMC algorithms permit full posterior inference
(e.g., credible intervals) even when the normality approximation based on large sample
theory is insufficient, which is valuable here because the sampling distributions of pi,
Se, Sp, PPV, NPV, LR+ and LR− are often skewed and the number of studies in
the meta-analysis is relatively small or moderate (e.g., N < 30). Specifically, we will
draw posterior inference using Gibbs and Metropolis-Hastings sampling algorithms [63,
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64, 65, 66] with convergence assessed using trace plots, sample autocorrelations, and
statistical convergence diagnostic tests [67, 68].
Let p(η), p(α), p(β) and p(Σ) denote the prior distributions for η, α, β and Σ. We
take non-informative normal priors on η, α, β and a Wishart prior on the precision
matrix Σ−1 (inverse Wishart prior on Σ), denoted by
p(η) ∼ N(0, 102); p(α) ∼ N(0, 102); p(β) ∼ N(0, 102); p(Σ−1) ∼W (R, v), (3.5)
where R is a 3 by 3 matrix, and a small number is chosen as the degrees of freedom v
(v ≥ 3). The posterior distribution of η, α, β and Σ can be written as:
p(η, α, β,Σ|Data) ∝ L(θ|Data)p(η)p(α)p(β)p(Σ)
N∏
i=1
p(εi, µi, νi|Σ) (3.6)
where L(θ|data) depends on (η, α, β) through pii = g−1(η + εi), Sei = g−1(α+ µi) and
Spi = g
−1(β + νi), and g−1(·) is the inverse function of the link function g(·). When
study-level covariates are included in the link functions, plug in pii = g
−1(η0+η1Xi+εi),
Sei = g
−1(α0 +α1W i + µi) and Spi = g−1(β0 + β1Zi + νi) instead. Here we focus on
the model without covariates for simplicity of the presentation.
Using the MCMC samples of η, α, and β, the posterior samples for population-
averaged PPV, NPV, LR+, LR− can be approximated by the following formulas:
PPV =
g−1(η)g−1(α)
g−1(η)g−1(α) + {1− g−1(η)}{1− g−1(β)}
NPV =
{1− g−1(η)}g−1(β)
{1− g−1(η)}g−1(β) + g−1(η){1− g−1(α)}
LR+ = g−1(α)/{1− g−1(β)}, LR− = {1− g−1(α)}/g−1(β)
3.2 Simulation
3.2.1 Simulation design
We conduct 12 sets of simulations to compare the proposed Bayesian hybrid GLMM
(3.1) to two alternative approaches which researchers are likely to apply in practice: 1) a
complete case analysis approach in which subjects not verified are ignored (model 3.2);
and 2) a trivariate GLMM approach in which case-control studies are excluded from the
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analysis (model 3.3). To fit model 3.2, case-control and cohort studies are combined as in
the hybrid GLMM, while the missing counts are excluded. To fit model 3.3, the missing
counts are accounted for as in the hybrid GLMM, while all case-control studies are
excluded from the data. To investigate the performance of the proposed hybrid GLMM,
for each generated dataset, we fit the hybrid GLMM, model 3.2 and model 3.3 separately
using R package BRugs [69]. Each dataset contains equal numbers of case-control and
cohort studies, where cohort studies are subject to partial verification. The probabilities
of missing a reference test are 0.2 and 0.8, given diagnostic test results being positive and
negative, respectively. The median prevalence is set to be 0.2 with the variances as σ2ε =
σ2µ = σ
2
ν = 1, and the number of subjects per study is chosen to be similar to the case
studies in Section 3.3. Specifically, we consider 12 settings with small (10) or moderate
(30) number of studies in a meta-analysis and high sensitivity (specificity) as 0.9 (0.95),
or low sensitivity (specificity) as 0.7 (0.8), respectively. To evaluate the impact of
the correlation structure, the correlation parameters (ρεµ, ρεν , ρµν) are chosen as (0, 0,
0), (0.5, −0.5, −0.5) or (0.8, −0.8, −0.8) to correspond to no correlation, moderate
or strong correlations among disease prevalence and test sensitivity and specificity (in
logit scale). We assume a positive correlation between pii and Sei as it is likely to
happen when population with higher prevalence may have more patients with clear-cut
disease condition, leading to a higher sensitivity. However, a negative correlation was
also observed in some studies[21]. For each setting, 2000 replicates are generated using
the trivariate logit-normal random effects model. The posterior statistics (median and
95% equal tailed credible interval) are summarized from 10000 posterior samples with
5000 burn-in iterations. Model performance is evaluated by comparing bias, relative
efficiency (RE) and 95% equal tailed credible interval coverage probability (CP) of the
three models. The REs are calculated as the ratio of the variances of estimates from
the hybrid model and the variances of the estimates from an alternative model. The
larger RE, the more efficient the estimate.
3.2.2 Simulation results
We summarized in Table 3.2 the bias, RE and CP of estimated overall Se, Sp, pi, NPV
and PPV for settings with 30 studies and median Se/Sp as 0.7/0.8. Simulation results
under other simulation settings are attached in Appendix B. Under all settings, the
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hybrid GLMM gives nearly unbiased estimates and satisfactory CP of Se, Sp, pi, PPV
and NPV that are close to the nominal level of 95%.
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Table 3.2: Summary of 2000 simulations with data generated from settings with 30 studies, true Se (Sp)=0.7 (0.8) and
different correlation assumptions.
Sp Se pi PPV NPV
Corra Modelb Bias RE CP Bias RE CP Bias RE CP Bias RE CP Bias RE CP
0 3.1 0 1 0.93 0 1 0.94 0.01 1 0.92 0.01 1 0.93 −0.01 1 0.93
0 3.2 −0.13 NA 0.29 0.1 NA 0.42 0.09 NA 0.71 0.02 NA 0.92 −0.02 NA 0.88
0 3.3 −0.01 0.47 0.93 0 0.29 0.93 0.01 1.07 0.93 0 0.83 0.94 −0.01 0.62 0.93
0.5 3.1 0 1 0.94 0 1 0.95 0.01 1 0.93 0 1 0.94 0 1 0.94
0.5 3.2 −0.13 NA 0.26 0.11 NA 0.34 0.06 NA 0.84 −0.01 NA 0.93 −0.01 NA 0.94
0.5 3.3 −0.01 0.5 0.94 0.02 0.32 0.94 0.01 0.95 0.93 0 0.89 0.95 0 0.68 0.95
0.8 3.1 0 1 0.93 0 1 0.94 0 1 0.95 0 1 0.95 0 1 0.96
0.8 3.2 −0.13 NA 0.29 0.11 NA 0.3 0.04 NA 0.88 −0.03 NA 0.94 0.01 NA 0.96
0.8 3.3 0 0.48 0.93 0.03 0.33 0.94 0 0.75 0.94 0.01 0.89 0.97 0.01 0.56 0.96
aCorr = 0 : (ρεµ, ρεν , ρµν) = (0, 0, 0), Corr = 0.5 : (ρεµ, ρεν , ρµν) = (0.5,−0.5,−0.5), Corr = 0.8 : (ρεµ, ρεν , ρµν) =
(0.8,−0.8,−0.8).
bModel = 3.1: Hybrid GLMM; Model = 3.2: a complete case analysis approach in which subjects not verified are
ignored; Model = 3.3: a trivariate GLMM approach in which case-control studies are excluded from the analysis.
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As expected, when the partial verification is ignored as in model 3.2, some of the
posterior estimates were considerably biased with grossly small CP. Under our simu-
lation assumptions, specificities are under-estimated, and prevalences and sensitivities
are over-estimated, which agrees with the illustrative example described in the intro-
duction. An intuitive explanation is that if we assume ωi1m = 0 and ωi0m > 0 such
that partial verification would decrease ni10 and ni00 but ni11 and ni10 remain the same,
leading to increased Se and decreased Sp estimates. From the simulations we also ob-
serve that the bias in pi is larger when true Se (Sp) was 0.9 (0.95) (ranges from 0.13
to 0.2) than when true Se (Sp) was 0.7 (0.8) (ranges from 0.04 to 0.11), respectively.
On the contrary, Sp and Se estimates are more biased when true Se (Sp) is 0.7 (0.8)
(ranges from 0.04 to 0.14 and from 0.09 to 0.11 respectively) than when true Se (Sp)
is 0.9 (0.95) (ranges from 0.01 to 0.04 and from 0.03 to 0.04 respectively). Because the
estimates are biased, we do not calculate the RE of these estimates. Estimates of PPV
and NPV from model 3.2 are nearly unbiased. Under the MAR assumption, we have
P (V = 1|Dis = 1, T = 1) = P (V = 1|T = 1), where V = 1 indicates verification of dis-
ease status, which would imply that P (Dis = 1|V = 1, Y = 1) = P (Dis = 1|Y = 1)[1].
When only cohort studies are included as in model 3.3, the estimates are nearly
unbiased and the CPs remain close to the nominal level. Specifically, for estimation of
prevalence, when there is no correlation, model 3 performs as well as the hybrid GLMM
because only the cohort studies have information of pi. However, as the correlation
becomes larger, the RE of model 3.3 becomes smaller indicating the hybrid GLMM
is gaining efficiency. This is because information of estimating prevalence is borrowed
from Se and Sp estimates from case-control studies. For estimations of Se and Sp,
substantial loss of efficiency can be observed using model 3.3 with REs around 0.3
and 0.5. The reason is that half of the whole study set (the case-control studies) are
discarded in model 3.3, which contains important information to estimate Se and Sp.
For estimations of PPV and NPV, loss of efficiency can also be observed with REs
ranging from 0.76 to 0.92, and from 0.44 to 0.69, respectively. Generally, the relative
efficiencies indicate that estimates from hybrid model are preferable. In summary, the
hybrid model performs well in correcting partial verification bias and gaining efficiency
by combining the information from cohort and case-control studies.
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3.3 Case study
3.3.1 Meta-analysis of gadolinium-enhanced MRI in detecting lymph
node metastases
We reanalyze the meta-analysis conducted by Klerkx et al. [23] using the proposed ap-
proach. Thirty-two studies were reported assessing diagnostic accuracy of gadolinium-
enhanced MRI in detecting lymph node metastases, with histopathology test as the
reference gold standard test. A bivariate random effects model [11] was applied by
Klerkx et al. [23]. Overall sensitivity and specificity were estimated as 0.72 with 95%
confidence interval (0.66, 0.79) and 0.87 with 95% confidence interval (0.82, 0.91), re-
spectively. Data for each study is reported in the systematic review, as well as the
QUADAS [28] quality assessment checklist.
The QUADAS criterion is used to classify case-control studies and studies with
partial verification. The 1st QUADAS criterion is whether patients were representative
of practice and six studies were reported as “No” or “Not Specified”. These studies are
considered as case-control studies and the rest as cohort studies in our analysis. The 5th
QUADAS criterion is whether all subjects were verified by the reference standard or not.
Nine cohort studies reported as “No”. Among them, we failed to extract missing counts
from two studies (study 13 and 25 in Table A.1 of Appendix A), thus are treated as
having no partial verification in the analysis. The remaining seven studies are considered
as having partial verification. Specific counts of n1m and n0m are extracted for studies 6,
11 and 20 . However, four studies only indicated total numbers of patients not verified,
while specific numbers of n1m and n0m are unclear. In practice, efforts should be made
to recover missing values. Studies with missing values should be discarded to avoid bias.
In the MRI study, the original papers from studies 10, 15, 16 and 22 were examined but
failed to recover missing values. However, for purpose of illustration of our method, we
assign all missing subjects as diagnostic test positive (n0m=0) for simplicity.
Model fitting via bayesian approach
We fit the data using the hybrid GLMM with logit link function using WinBUGS [70]
to draw posterior samples. Model 3.2 and model 3.3 are also fitted for comparison.
Non-informative normal priors N(0, 102) are given to η, α and β and a Wishart prior
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W (R,v) is given to the precision matrix Σ−1 as in (3.5). The degree of freedom v
in the Wishart prior is set as v = 4, as pointed out by Tokuda et al. that when
v = k + 1, where k is the dimension of Σ, the correlation coefficient parameters in
Σ will have an approximately Uniform (−1, 1) vague prior [71, 72]. A scaled Wishart
prior method is applied by setting v = 4 and R as a 3 by 3 identity matrix. Wishart
prior is known as a conjugate prior for the precision matrix in a multivariate normal
distribution. However, it is restricted in that it implies the same prior assumption on all
of the variance components. The scaled Wishart prior method allows the flexibility of
having separate priors on each of the precision parameter, while keeping the conjugacy
property [73]. The same priors are applied to model 3.2 and model 3.3. After 100,000
burn-in samples, 1,000,000 posterior samples are collected. The median estimates and
95% credible interval (CI) of interested parameters are presented in Table 3.3, where
the estimates from hybrid GLMM are in bold.
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Table 3.3: Median estimates and 95% CI for meta-analysis of MRI: comparing two prior families (the scaled and
unscaled inverse Wishart prior) and comparing different choices of the Wishart prior parameter R.
Scaled Method Unscaled Method
Hybrid GLMM Model 3.2 Model 3.3 Hybrid GLMM Hybrid GLMM
Parameters R=I R=I R=I R=I diag(R)=(9.8,3.3,2.2)
pi 0.39 (0.35,0.44) 0.37 (0.32,0.42) 0.39 (0.35,0.44) 0.39 (0.34, 0.45) 0.39 (0.34,0.45)
σε 0.32 (0.08,0.57) 0.45 (0.22,0.73) 0.32 (0.10,0.57) 0.46 (0.31,0.69) 0.47 (0.33,0.69)
Se 0.76 (0.70,0.82) 0.73 (0.66,0.78) 0.77 (0.71,0.83) 0.77 (0.70,0.82) 0.78 (0.69,0.85)
σµ 0.55 (0.21,0.99) 0.47 (0.17,0.92) 0.47 (0.10,0.99) 0.64 (0.41,1.00) 1.03 (0.76,1.45)
Sp 0.84 (0.79,0.89) 0.87 (0.82,0.91) 0.85 (0.79,0.90) 0.84 (0.79,0.89) 0.85 (0.79,0.90)
σν 0.92 (0.62,1.33) 0.89 (0.62,1.31) 0.74 (0.41,1.22) 0.88 (0.61,1.27) 0.97 (0.69,1.37)
ρµν −0.47 (−0.92,0.15) −0.56 (−0.96,0.11) −0.60 (−0.97,0.31) −0.39 (−0.76,0.17) −0.49 (−0.83,0.12)
ρεµ 0.08 (−0.74,0.85) 0.37 (−0.50,0.94) 0.16 (−0.71,0.89) −0.01 (−0.55,0.56) 0.04 (−0.56,0.61)
ρεν −0.42 (−0.92,0.40) −0.57 (−0.93,0.09) −0.41 (−0.91,0.36) −0.30 (−0.72,0.31) −0.34 (−0.76,0.31)
NPV 0.85 (0.80,0.88) 0.85 (0.80,0.88) 0.85 (0.81,0.89) 0.85 (0.80,0.89) 0.86 (0.80,0.91)
PPV 0.76 (0.69,0.83) 0.76 (0.69,0.82) 0.76 (0.69,0.83) 0.76 (0.69,0.83) 0.77 (0.69,0.84)
LR+ 3.22 (2.37,4.52) 2.65 (1.98,3.61) 3.34 (2.45,4.82) 3.25 (2.35,4.63) 3.53 (2.25,5.76)
LR− 0.31 (0.22,0.42) 0.38 (0.28,0.51) 0.30 (0.21,0.41) 0.31 (0.22,0.43) 0.28 (0.17,0.44)
Model 3.2 stands for a complete-case analysis where case-control and cohort studies are combined while partial
verification are ignored and model 3.3 stands for a trivariate GLMM where partial verificaiton bias is adjusted while
case-control studies are excluded.
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The hybrid GLMM gives posterior median estimates of overall sensitivity as 0.76,
which is 0.04 higher than the estimate reported by Klerkx et al. [23] and with a slightly
narrower 95% CI, i.e., an interval of (0.70, 0.82) from the hybrid GLMM versus (0.66,
0.79) from the bivariate random effects method. The posterior median is 0.84 for the
overall specificity, which is 0.03 lower than the bivariate model estimates. In addition,
our approach allows the estimation of disease prevalence and possible correlations among
prevalence, Se and Sp. We also presented posterior estimates of PPV, NPV, LR+ and
LR− in Table 3.3. In this case-study, the estimates from hybrid GLMM and from
model 3 are very similar as only 6 of the 32 studies are case-control studies, e.g., the
median sensitivity is estimated as 0.762 in hybrid model and 0.770 in model 3.3. The
quantile contours of posterior estimates Se versus pi, Sp versus pi, Se versus Sp and
NPV versus PPV at quantile levels 0.25, 0.5, 0.75, 0.90 and 0.95 are presented in Figure
3.1 A-D, respectively. Figure 3.1A indicates slightly positive correlation between Se
and pi. Negative correlation can be observed between Sp and pi and between Se and
Sp in Figure 3.1B and 3.1C. This observation agrees with the posterior estimates of
correlation coefficients in Table 3.3: posterior ρεµ, ρεν and ρµν has median estimates as
0.08, −0.42 and −0.47. Slightly negative correlation is shown in Figure 3.1D between
NPV and PPV. The observed estimates of Se and Sp for each study and the posterior
estimates from the hybrid GLMM and model 3.2 are ploted in Figure 3.2. The plot
shows that different approaches can lead to different posterior estimates.
Sensitivity analysis to prior distributions for Σ−1
In addition to the scaled Wishart prior, an unscaled Wishart prior is commonly used
in which no scale parameter is imposed on the precision matrix components. For the
unscaled Wishart prior for Σ−1, there are several applicable selections of matrix R: the
identity matrix [74], or a diagonal matrix with diagonal entries chosen to be close to
the diagonal elements of posterior precision matrix [62]. In the latter option, previous
estimates of the precision matrix can serve as a prior for further estimations. As the
scaled Wishart prior in previous paragraph gives posterior variance parameter estimates
close to (0.322, 0.552, 0.912), we choose the Wishart prior parameter R to have diagonal
entries close to (0.322, 0.552, 0.912)−1 ≈ (9.8, 3.3, 1.2). Thus, to study whether the
posterior estimates are sensitive to different prior assumptions, we fit the data via two
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Figure 3.1: Quantile contours of posterior densities from estimates of the meta-analysis
of gadolinium-enhanced MRI in detecting lymph node metastases assuming scaled
Wishart prior. A-D plot posterior Se versus prevalence (pi), Sp versus pi, Se versus
Sp and PPV versus NPV, respectively, at quantile levels 0.25, 0.5, 0.75, 0.9 and 0.95.
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Figure 3.2: SROC curves from the Hybrid GLMM and the bivariate GLMM using MLE
approach. Solid lines are the SROC curve from the hybrid GLMM estimates and the
95% prediction region for the summary point estimates of Se and Sp. Dashed lines are
the SROC curve from the bivaraite estimates and the 95% prediction region for the
summary point estimates of Se and Sp. Black and gray circles are the observed Se and
Sp from studies with and without missing counts, respectively. Red and blue triangles
are the posterior estimates of Se and Sp from the Hybrid GLMM and the Bivariate
GLMM ignoring partial verification, respectively.
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unscaled Wishart priors: the identity matrix and a diagonal matrix with elements as
(9.8, 3.3, 1.2). The fitted results are shown in Table 3.3 under unscaled methods. It
shows that different priors have little impact on the posterior median Sp or pi estimates.
To visually study the impact of different priors on posterior estimates, panel A of
Figure 3.3 plots posterior densities of Se, Sp and pi and panel B of Figure 3.3 plots
posterior densities of PPV and NPV under different prior assumptions. Figure 3.3
shows that different priors have little impact on the posterior Sp or pi estimates. The
unscaled R = diag(9.8, 3.3, 1.2) prior gives negligibly larger Se, PPV and NPV posterior
estimates than the other two priors. The small impact of prior assumption is consistent
with intuition and the literature. For example, Lambert et al. pointed out that in a
univariate setting that relatively large study sizes (15 or 30 in their simulation settings)
would be less influenced by the prior of the scale parameter than small study size (5 in
their simulation settings) [75].
An alternative maximum likelihood (MLE) approach
A referee has suggested considering a frequentist MLE approach as an alternative to
obtain parameter estimates. Simulation studies comparing the Bayesian and MLE ap-
proaches are available in the literature [18]. We present here the estimates of MRI
meta-analysis study via MLE approach, which was carried out by SAS NLMIXED pro-
cedure. The median estimate (95% confidence interval) is 0.39 (0.30, 0.45) for disease
prevalence, 0.77 (0.70, 0.83) for sensitiviy and 0.85 (0.80, 0.90) for specificity. The bi-
variate GLMM [5, 10, 4] ignoring partial verification was also fitted via SAS NLMIXED
procedure, where sensitivity is estimated to be 0.72 (0.66, 0.79) and specificity is esti-
mated to be 0.87 (0.82, 0.92). The estimates are close to our posterior estimates from
model 1 and model 3.2 via the Bayesian approach (Table 3.3). The summary receiver
operating characteristic (SROC) curves was first proposed by Moses et al. [54] to reflect
the trade-off between sensitivity and specificity caused by implicit thresholds and bigger
area under curve (AUC) suggests better test performance. SROC curves using the MLE
estimates from the hybrid GLMM and the bivariate GLMM approaches are plotted for
comparison [2, 11, 45] (Figure 3.2). AUC are estimated to be 0.83 and 0.81 from the
hybrid GLMM and the bivariate GLMM, respectively. The posterior Se and Sp esti-
mates and AUC estimates from the hybrid GLMM and the bivariate GLMM ignoring
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Figure 3.3: Density plots of posterior estimates of the meta-analysis of gadolinium-
enhanced MRI in detecting lymph node metastases under different prior assumptions.
Panel A plots posterior densities of Se, Sp and prevalence (pi). Panel B plots posteriors
densities of PPV and NPV.
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partial verification are different, indicating that ignoring partial verification can lead
to different conclusions on test accuracy. Thus, it is important to account for partial
verification in a meta-analysis of diagnostic tests.
3.3.2 Meta-analysis of adrenal fluorine-18 fluorodeoxyglucose (FDG)
positron emission tomography (PET) in characterizing adrenal
masses
Boland et al. conducted a systematic review and meta-analysis of 21 cohort studies
about test accuracy of FDG-PET in characterizing adrenal masses[76]. The reference
standard tests used in the 21 cohort studies include surgery, percutaneous biopsy and
follow-up CT. FDG-PET is concluded to be highly accurate in detecting and differ-
entiating malignant adrenal disease. The authors applied the bivarate random effects
model and reported that the mean sensitivity, specificity of FDG-PET are estimated to
be 0.97 (95% confidence interval: 0.93, 0.98) and 0.91 (95% confidence interval: 0.87,
0.94), respectively[76]. However, the authors evaluated the methodologic quality of the
included studies by the QUADAS criterias and 18 out of the 21 studies were at risk of
partial verification bias. Among the 18 studies with missing counts, we were able to
extract the total missing counts for 8 studies from the original papers. The cell counts
of each study are reported in Table A.2 of Appendix A. Again, we impose a strong as-
sumption on studies with only total missing counts available that the missing subjects
were all tested negative by FDG-PET. We make this assumption here to creat a viola-
tion of the missing completely at random situation to show difference in estimates from
the hybrid GLMM and from model 3.2. Under this assumption, sensitivity estimates
will be conservative. Again, in practice, missing values should be recovered as much as
possible and studies with missing values should be discarded to avoid bias.
We fit this data by the hybrid GLMM and model 3.2. In both models we use
the same priors and number of posterior samples as in the meta-analysis of MRI data
(section 3.3.1). We do not fit this example by model 3.3, because all the included studies
in this meta-analysis are cohort studies. The estimates of interesting parameters are
presented in Table 3.4. The hybrid GLMM estimates the overall median (95% CI)
sensitivity, specificity and prevalence as 0.94 (95% CI: 0.91, 0.97), 0.93 (95% CI: 0.90,
0.95) and 0.39 (95% CI: 0.31, 0.47), respectively. The overall sensitivity, specificity
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Table 3.4: Median estimates and 95% CI for meta-analysis of FDG PET: comparing
the hybrid GLMM and model 3.2 where partial verification is ignored
Parameter Hybrid GLMM Model 3.2
pi 0.39 (0.31, 0.47) 0.45 (0.37, 0.53)
σε 0.68 (0.47, 1.01) 0.63 (0.43, 0.95)
Se 0.94 (0.91, 0.97) 0.96 (0.93, 0.98)
σµ 0.68 (0.23, 1.51) 0.71 (0.23, 1.54)
Sp 0.93 (0.90, 0.95) 0.90 (0.87, 0.94)
σν 0.54 (0.22, 1.08) 0.51 (0.22, 1)
ρµν 0.78 (-0.37, 0.97) 0.80 (-0.28, 0.97)
ρεµ -0.07 (-0.76, 0.74) -0.05 (-0.80, 0.73)
ρεν -0.46 (-0.89, 0.37) -0.31 (-0.85, 0.49)
NPV 0.96 (0.93, 0.98) 096 (0.93, 0.98)
PPV 0.89 (0.84, 0.93) 0.89 (0.84, 0.93)
LR+ 16.83 (9.94, 37.97) 21.77 (12.85, 49.75)
LR− 0.06 (0.03, 0.10) 0.05 (0.02, 0.08)
and prevalence estimates from model 3.2 are 0.96 (95% CI: 0.93, 0.98), 0.90 (95% CI:
0.87, 0.94) and 0.45 (95% CI: 0.37, 0.53), respectively. The trivariate GLMM ignoring
partial verification overestimate sensitivity by 0.03, underestimate specificity by 0.03
and overestimate prevalence by 0.06. Again, this example shows that ignoring partial
verification bias can give different estimates for the test accuracy parameters.
3.4 Discussion
In this chapter we proposed a hybrid Bayesian hierarchical model to combine cohort and
case-control studies in meta-analysis of diagnostic tests to account for disease prevalence
and to correct partial verification bias. In general, this approach improves the precision
of the estimates of test accuracies and predictive values by using all available informa-
tion, and can be easily applied in practice using free downloadable software R [77] and
WinBUGS [70].
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Simulation studies are performed under a variety of settings to compare the per-
formance of the proposed method with two practical alternative approaches of either
ignoring unverified subjects or excluding case-control studies. We showed that ignoring
unverified subjects can lead to substantial bias and excluding case-control studies can
lead to substantial loss of efficiency. Overall the simulation results show that the hybrid
approach gives nearly unbiased posterior medians under all settings considered. The
coverage probabilities of posterior intervals are close to the nominal level. Thus in the
presence of mixed study designs and partial verification bias in a meta-analysis, the
hybrid GLMM should be preferred over the two common alternative approaches.
Two case studies are used to illustrate our method. The first case study evaluates
the diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging in detect-
ing lymph node metastases. After combining the case-control and cohort studies and
correcting for partial verification bias, compared to the original report, slightly higher
sensitivity and lower specificity point estimates are obtained. The direction of bias on
Se and Sp when ignoring the missing subjects is opposite of the simulation studies be-
cause we assume some studies have higher missing probability in MRI tested positives as
n0m = 0. This can be intuitively explained under an extreme assumption that ωi0m = 0
and ωi1m > 0 such that partial verification would decrease ni11 and ni10 but keep ni10
and ni00 the same, leading to decreased Se and increased Sp estimates. In addition, our
approach provides overall estimate of disease prevalence, which is required for comput-
ing other clinical useful indices such as PPV and NPV. The second case study evaluates
the diagnostic accuracy of FDG-PET in characterizing adrenal masses. After correct-
ing partial verification bias, lower sensitivity and prevalence, and higher specificity are
estimated than the bivariate random effects model.
An important question is what is an approriate sample size for such meta-analysis?
Our simulation settings assumed sample size of 10 and 30 studies and lead to nearly
unbiased estimates. As we have taken a full Bayesian approach, this becomes an even
more intriguing question as the needed sample size may depend on whether there are
informative priors for some parameters to improve estimation. In practice, sample
size of meta-analysis varies largely. Davey et al. [78] summarized that among 22,453
meta-analyses with at least two studies, the median number of studies is three and
inter-quartile ranges from 2 to 6. As our hybrid GLMM is a random effects model,
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larger sample sizes may be needed.
In this chapter, we assume that the reference test is a gold standard. In practice,
however, the reference test may be imperfect and subject to misclassification. Extensions
to relax the assumption of perfect reference test are currently under investigation. In
such settings, every subjects true disease status is unknown and the imperfect tests may
be correlated conditional on the latent disease status, inducing additional complexity
for the estimation of test performance. Effort has been devoted in this regard. For
example, Chu et al. [18] talked about adjusting for missing data with imperfect reference
test. Dendukuri et al. [20] proposed a Bayesian approach to access overall sensitivity
and specificity under absence of gold standard assumption, extending the hierarchical
summary receiver operating characteristic method by Rutter and Gatsonis [2]. Both
approaches included conditional dependence between the two tests through additional
covariance terms. However, restrictions on the covariance terms have to be imposed to
ensure well-defined probability models.
Another assumption to be relaxed in future research is the MAR assumption. We
consider the MAR assumption to be practical because in many studies whether a sub-
ject is being tested by the reference test is merely dependent on the outcome of the
diagnostic test and other observed characteristics. However, in some studies such as
longitudinal studies the MNAR assumption may be more appropriate. Baker [38] dis-
cussed maximum likelihood estimates for the situation with multiple tests and Kosinski
and Barnhart [37] presented a general likelihood-based regression approach, based on
the conditional selection model by Little [79], that can flexibly account for covariates and
model different missing data mechanisms. Future development is needed to incorporate
these approaches in meta-analysis settings.
Chapter 4
A trivariate meta-analysis of
diagnostic studies accounting for
prevalence and non-evaluable
subjects: re-evaluation of the
meta-analysis of coronary CT
angiography studies
Chapter 3 focuses on adjusting partial verification bias caused by subjects with un-
verified disease status. In this chapter, we discuss the situation where subjects are non-
evaluable by the index test. A recent paper proposed an intent-to-diagnose approach to
handle non-evaluable index test results and discussed three alternative approaches, with
an application to the meta-analysis of coronary CT angiography diagnostic accuracy
studies [41]. For ease of presentation, we name the three alternative approaches as Model
4.1 (non-evaluable subjects are excluded from the study), Model 4.2 (non-evaluable
diseased subjects are taken as true positives and non-diseased subjects are taken as false
positives) and Model 4.3 (non-evaluable diseased subjects are taken as false negatives
and non-diseased subjects are taken as true negatives). In this chapter we propose an
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extended TGLMM [80] to handle non-evaluable index test results in Section 4.1. The
performance of the intent-to-diagnose approach, the three alternative approaches and
the extended TGLMM approach is examined by extensive simulation studies in Section
4.2. The meta-analysis of coronary CT angiography diagnostic accuracy studies is re-
evaluated by the extended TGLMM in Section 4.3. Finally, we conclude this chapter
with some discussions in Section 4.4.
4.1 Methods
We generalize the TGLMM approach to account for missing index test outcomes by
extending the “classic” 2 × 2 table (Table 2.2) to Table 4.1, using same notations in
Chapter 3. Each cell in Table 4.1 reports the cell count and cell probability corre-
sponding to a combination of index test and disease outcomes in study i. The missing
probabilities and disease prevalence are incorporated in the cell probabilities in Table
4.1.
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Table 4.1: 3× 2 table accounting for prevalence and missing index test results.
Gold standard
Index Test + − Total
ni11 ni10 ni1+
+ (1− ωim1)piiSei (1− ωim0)(1− pii)(1− Spi) (1− ωim1)piiSei + (1− ωim0)(1− pii)(1− Spi)
ni01 ni00 ni0+
− (1− ωim1)pii(1− Sei) (1− ωim0)(1− pii)Spi (1− ωim1)pii(1− Sei) + (1− ωim0)(1− pii)Spi
nim1 nim0 nim+
Missing ωim1pii ωim0(1− pii) ωim1pii + ωim0(1− pii)
ni+1 ni+0 ni++
Total pii 1− pii 1
Each cell reports the cell count and cell probability corresponding to a combination of index test and disease outcomes
in study i.
nitd denotes the cell counts in study i with index test outcome T = t and reference test outcome Dis = d, where
t = 1, 0,m stands for positive, negative and missing, and d = 1, 0 denotes positive and negative.
Sei, Spi and pii are sensitivity, specificity and prevalence of study i, respectively. ωimd denotes the missing probability
of index test given disease status d in study i.
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Assuming a multinomial distribution, the likelihood for θi = (Sei, Spi, pii) and ωi =
(ωim1, ωim0) given data (cell counts) is:
L(θi,ωi|Data) ∝ {(1− ωim1)piiSei}ni11{(1− ωim0)(1− pii)(1− Spi)}ni10
{(1− ωim1)pii(1− Sei)}ni01{(1− ωim0)(1− pii)Spi}ni00
(piiωim1)
nim1{(1− pii)ωim0}nim0
(4.1)
It is straight forward to tell from (4.1) that L(θi,ωi|Data) ∝ L(θi|Data)× L(ωi|Data),
where the log-likelihood of θi is:
logL(θi|Data) = ni11{log(pii) + log(Sei)}+ ni10{log(1− pii) + log(1− Spi)}
+ ni01{log(pii) + log(1− Sei)}+ ni00{log(1− pii) + log(Spi)}
+ nim1log(pii) + nim0log(1− pii)
Let θ = {θi}. Assuming independence among studies conditional on θi, the total log
likelihood of θ is:
logL(θ|Data) =
N∑
i=1
logL(θi|Data) (4.2)
Let logit(pii) = η + εi, logit(Sei) = α + µi and logit(Spi) = β + νi. (η, α, β) are
the fixed effect parameters such that median pi, Se and Sp can be approximated as
logit−1(ηˆ), logit−1(αˆ) and logit−1(βˆ), respectively. The random effect vector (εi, µi, νi)
is assumed to be trivariate normally distributed:
(εi, µi, νi)
T ∼MVN(0,Σ), Σ =

σ2ε ρεµσµσε ρενσνσε
σ2µ ρµνσνσµ
σ2ν
 ,
where the diagonal elements in Σ account for between-study variations of pi, Se and
Sp and the off-diagnonal elements take care of potential correlations among the three
parameters.
Median PPV, NPV, LR+ and LR− and median AUC (AUCM ) can be approximated
as [45]:
PPV =
logit−1(η)logit−1(α)
logit−1(η)logit−1(α) + {1− logit−1(η)}{1− logit−1(β)} ,
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NPV =
{1− logit−1(η)}logit−1(β)
{1− logit−1(η)}logit−1(β) + logit−1(η){1− logit−1(α)} ,
LR+ = logit−1(α)/{1− logit−1(β)}, LR− = {1− logit−1(α)}/logit−1(β),
AUCM =
∫ 1
0
logit−1{(α− ρµνβσµ)/σν + ρµνσµ/σν [logit(1− Sp)] dSp.
The extended TGLMM can be fitted by standard software like SAS NLMIXED
procedure, which implements an adaptive Gaussian quadrature to approximate the log-
likelihood in (4.2) integrated on random effects with dual quasi-Newton optimization
techniques. The NLMIXED procedure directly outputs fixed effects estimates ηˆ, αˆ and βˆ
and can provide median prevalence, Se, Sp, PPV, NPV, LR+, LR− estimates and their
confidence intervals through the “estimate” statements. Sample SAS code is available
in the Appendix.
4.2 Simulations
4.2.1 Simulation Scenarios
We conduct simulation studies under three missing scenarios to systematically evalu-
ate the performance of the proposed extended TGLMM approach and the approaches
discussed in Schuetz et al. [41]: missing probabilities for diseased and non-diseased
subjects are same (0.1), or missing probability of diseased group (0.1) is smaller than
non-diseased group (0.2), or missing probability of diseased group (0.2) is larger than
non-diseased group (0.1). All three scenarios satisfy the MAR assumption, and the first
scenario is in fact MCAR [46]. True sensitivity and specificity are 0.7 and 0.9, disease
prevalence is 0.25 and variances of Se, Sp and prevalence are 1 on logit scale. These
assumptions mimic a diagnostic test with relatively low sensitivity, high specificity and
a disease with moderate prevalence. A moderate positive correlation of 0.3 is assumed
between Se and pi, and moderate negative correlations of −0.3 are assumed between Sp
and pi and between Se and Sp, on logit scales. Such correlation directions were observed
in some meta-analysis studies[60, 43]. Intuitively, a population with higher prevalence
may have more diseased cases with clear disease symptoms, leading to increased sensi-
tivity. Under each setting, 5000 meta-analysis data sets are simulated with 30 studies in
each data set. pii, Sei and Spi for each study were generated according to the trivariate
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assumption described in Section 4.1. True and false positives, true and false negatives
and non-evaluable counts are sampled from the multinomial distribution in Table 4.1.
For each simulated meta-analysis data set, the extended TGLMM, Model 4.1-4.3 and
the intent-to-diagnose approach are fitted. Bias in percentage, mean standard error
(SE) and 95% confidence interval coverage probability (CP) are collected and compared
for estimates of sensitivity, specificity, prevalence, PPV, NPV, LR+ and LR−. Bias
in percentage is calculated by (δˆ − δ) × 100/δ, where δ is the true value and δˆ is the
estimator.
4.2.2 Simulation Results
Table 4.2 shows the simulation results under different scenarios. When MCAR (ωm1 =
ωm0 = 0.1), disease prevalence estimates from all five models are nearly unbiased (bias
less than 1%). The extended TGLMM and Model 4.1 both give nearly unbiased esti-
mates (bias less than 1.6%) and nominal coverage probabilities around 93% for Se, Sp,
PPV, NPV, LR+ and LR− estimates. Model 4.2 over-estimates sensitivity and under-
estimates specificity: bias of sensitivity estimate is 4.6% and bias of specificity estimates
is 11.9%. Estimates of PPV and LR+ are more biased (22.6% bias for PPV and 49.2%
bias for LR+). Using Model 4.3 sensitivities are largely under-estimated (12.6% bias)
and specificities are over-estimated (1.1% bias). The intent-to-diagnose approach largely
under-estimates both sensitivity and specificity (12.6% and 11.9% bias, respectively).
The CPs for some estimates from Model 4.2 and 4.3 and the intent-to-diagnose ap-
proach can be as low as 0 (e.g., specificity estimates from Model 4.2), indicating that
none of the confidence intervals cover the true values. When missing probability of
the diseased group is smaller than the non-diseased group (ωm1 = 0.1, ωm0 = 0.2), the
extended TGLMM and Model 4.1 both give nearly unbiased estimates (bias around
0.1%) of sensitivity and specificity. However, Model 4.1 over-estimates disease preva-
lence (9.6% bias) while the extended TGLMM gives nearly unbiased (bias within 1%)
estimate of prevalence. As a consequence, Model 4.1 gives biased estimates of PPV
and NPV (3.1% and 1.3%, respectively), while the extended TGLMM provides nearly
unbiased estimates for all parameters (within 2%). Again, under this scenario, the
intent-to-diagnose approach largely under-estimates sensitivity, specificity, PPV, NPV
and LR+ and over-estimates LR−, with CPs less than 40% and some as low as 0. On
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the other hand, when ωm1 = 0.2 and ωm0 = 0.1, the extended TGLMM and Model
4.1 again give nearly unbiased estimates (bias around 0.1%) of sensitivity and speci-
ficity. Model 4.1 under-estimates disease prevalence (8.4% bias) while the extended
TGLMM provides nearly unbiased estimates. The intent-to-diagnose approach largely
under-estimates sensitivity, specificity, PPV, NPV and LR+ and over-estimates LR−
and some CPs are as low as 0. When the missing probabilities for diseased and non-
diseased subjects are more unbalanced, we expect the estimates from Model 4.1-4.3 and
the intent-to-diagnose approach to have larger bias and smaller CP. In practice, how-
ever, depending on the test performance and missing probabilities, the direction and
magnitude of the bias from the four approaches discussed in Schuetz et al. [41] can be
different from what we observed in these simulation studies.
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Table 4.2: Simulation results under three scenarios of MAR assumption: equal or unequal missing probabilities for the diseased
and non-diseased groups.
Model TGLMM Model 4.1 Model 4.2 Model 4.3 Intent-to-diagnose
Estimate Bias% meanSE CP Bias% meanSE CP Bias% meanSE CP Bias% meanSE CP Bias% meanSE CP
ωm1 = ωm0 = 0.1
Se −0.3 0.041 0.94 −0.3 0.041 0.94 4.6 0.036 0.81 −12.6 0.037 0.33 −12.6 0.036 0.33
Sp −0.1 0.017 0.93 −0.1 0.017 0.93 −11.9 0.018 0 1.1 0.015 0.84 −11.9 0.017 0
pi 0.8 0.034 0.93 0.8 0.034 0.93 0.8 0.034 0.93 0.8 0.034 0.93 0.8 0.034 0.93
PPV −0.1 0.046 0.94 −0.3 0.046 0.94 −22.6 0.047 0.08 −0.9 0.046 0.94 −29 0.049 0.01
NPV −0.1 0.018 0.93 −0.1 0.018 0.93 −0.2 0.018 0.93 −2.9 0.020 0.81 −4.6 0.022 0.59
LR+ 1.6 1.188 0.92 1.6 1.189 0.93 −49.2 0.307 0 −0.5 1.160 0.92 −57.6 0.271 0
LR− 0.9 0.044 0.94 0.9 0.044 0.94 1.5 0.044 0.94 27.9 0.039 0.33 46.8 0.045 0.04
ωm1 = 0.1, ωm0 = 0.2
Se −0.1 0.041 0.94 −0.1 0.041 0.94 4.7 0.036 0.80 −12.3 0.036 0.34 −12.3 0.036 0.34
Sp −0.1 0.017 0.94 −0.1 0.017 0.94 −22.3 0.017 0 2.2 0.014 0.62 −22.3 0.017 0
pi 0.4 0.034 0.93 9.6 0.036 0.90 0.4 0.034 0.93 0.4 0.034 0.93 0.4 0.034 0.93
PPV −0.3 0.046 0.93 3.1 0.044 0.88 −36 0.047 0 2.7 0.044 0.89 −42.1 0.047 0
NPV −0.1 0.018 0.94 −1.3 0.020 0.93 −1.4 0.020 0.92 −2.7 0.020 0.83 −6.3 0.024 0.36
LR+ 1.4 1.195 0.94 1.4 1.194 0.94 −65.1 0.159 0 12.3 1.312 0.95 −70.8 0.147 0
LR− 0.6 0.044 0.93 0.6 0.044 0.93 14.7 0.050 0.85 26.1 0.038 0.39 66.1 0.051 0
ωm1 = 0.2, ωm0 = 0.1
Se -0.1 0.023 0.93 -0.1 0.023 0.93 8.7 0.018 0.12 -21 0.020 0 -21 0.019 0
Sp 0 0.009 0.93 0 0.009 0.93 -10.6 0.009 0 1.1 0.008 0.74 -10.6 0.009 0
Prev 0 0.018 0.93 -8.4 0.017 0.72 0 0.017 0.91 0 0.017 0.91 0 0.0168 0.89
PPV -0.1 0.025 0.93 -3.7 0.027 0.83 -19.1 0.025 0 -4 0.026 0.8 -30.6 0.025 0
NPV 0 0.010 0.92 1.1 0.009 0.76 1.1 0.009 0.74 -4.6 0.011 0.05 -6.2 0.012 0
LR+ 0.3 0.655 0.93 0.3 0.653 0.93 -44.1 0.196 0 -11.7 0.570 0.62 -59.3 0.154 0
LR- 0.3 0.025 0.93 0.3 0.025 0.93 -10.8 0.022 0.62 47.4 0.021 0 66.7 0.024 0
Bias in percentage(Bias%), mean standard error (meanSE) and 95% confidence interval coverage probability (CP)
are summarized for estimates of Se, Sp, pi, PPV, NPV, LR+ and LR− from different models.
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4.3 Re-evaluation of the meta-analysis of coronary CT an-
giography studies
Cardiac CT scans can be used to rule out stenoses, however, are found to be subject to
non-evaluable results. Schuetz et al.[41] performed a systematic search for diagnostic
accuracy studies of coronary CT angiography. The authors searched Medline, Embase
and ISI Web of Science databases for prospective studies using conventional coronary
angiography as the gold standard and have patients with non-evaluable CT images.
Eventually, 26 studies were included that reports cell counts in a 3 × 2 table as Table
4.1. The authors mentioned that the 3 × 2 table can be extended to a 3 × 3 table
for non-evaluable results of the gold standard, however such cases were rare (0.1%) in
this systematic review. We re-evaluate the 26 studies by the extended TGLMM and
compare to the estimates following the four approaches discussed in Schuetz et al.[41].
The fitted median estimates and 95% confidence intervals are reported in Table
4.3. The extended TGLMM accounting for missing subjects gives median sensitivity,
specificity, LR+, LR− and AUC estimates close to the estimates when non-evaluable
subjects are excluded as in Model 4.1. The median disease prevalence estimated from the
extended TGLMM is slightly lower than the estimate from Model 4.1. Model 4.2 gives
significantly lower specificity estimate and Model 4.3 gives lower sensitivity estimate.
The intent-to-diagnose approach provides lower estimates for sensitivity, specificity and
AUC as it is the most conservative approach. Figure 4.1 presents the estimated PPV and
NPV with 95% confidence bands versus prevalence, based on the overall sensitivity and
specificity estimates from the extended TGLMM and the intent-to-diagnose approach.
Figure 4.1 shows that as disease prevalence changes, PPV and NPV estimates from the
latter approach are not ever included in the 95% confidence band of the estimates from
the extended TGLMM, which suggests potential underestimation of PPV and NPV.
4.4 Conclusions
In this chapter, we propose an extended TGLMM approach to handle non-evaluable
index test subjects in meta-analysis of diagnostic tests. The extended TGLMM is
compared to an intent-to-diagnose approach and three alternative approaches proposed
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Figure 4.1: Overall PPV and NPV plot based on the extended TGLMM (denoted by
“TGLMM”) and the intent-to-diagnose approach. The solid and dashed lines are the
overall estimates of PPV and NPV from the extended TGLMM and the intent-to-
diagnose approach corresponding to different prevalences ranging from 0 to 1, respec-
tively. The dotted lines are the 95% confidence intervals of PPV and NPV estimates
from the extended TGLMM approach. The vertical dashed line is the overall prevalence
estimates from the meta-analysis of coronary CT angiography studies.
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Table 4.3: Median estimates and 95% confidence intervals (in brackets) for parameter
estimates using different methods
Method Sensitivity Specificity Prevalence PPV
TGLMM 98.0 (96.7,99.3) 87.5 (82.7,92.3) 47.8 (37.9,57.7) 87.8 (83.3,92.3)
Model 4.1 98.0 (96.7,99.3) 87.4 (82.5, 92.3) 49.3 (38.9,59.7) 88.4 (84,92.7)
Model 4.2 98.1 (96.9,99.3) 75.9 (69.3,82.5) 47.8 (37.9,57.8) 78.9 (71.9,85.9)
Model 4.3 91.7 (88.1,95.4) 89 (85.4,92.7) 47.8 (37.9,57.7) 88.4 (84.1,92.7)
Intent-to-diagnose 91.7 (88.1,95.3) 76.2 (69.7,82.6) 47.9 (37.9,57.9) 78 (70.2,85.7)
Method NPV LR+ LR− AUC
TGLMM 97.9 (96.4,99.5) 7.8 (4.8,10.9) 0.02 (0.01,0.04) 0.99 (0.96,1)
Model 4.1 97.8 (96.1,99.4) 7.8 (4.8,10.9) 0.02 (0.01,0.04) 0.99 (0.96,1)
Model 4.2 97.8 (96.2, 99.4) 4.1 (2.9,5.2) 0.02 (0.01,0.04) 0.98 (0.97,1)
Model 4.3 92.1 (88.4,95.8) 8.4 (5.5,11.3) 0.09 (0.05,0.14) 0.96 (0.93,0.99)
Intent-to-diagnose 90.9 (86.4,95.5) 3.8 (2.7,5.0) 0.11 (0.06,0.16) 0.93 (0.89,0.96)
by Schuetz et al.[41] through simulation studies and re-evaluaion of the meta-analysis
of coronary CT angiography studies.
In summary, by simulation studies we showed that under MAR assumption, exclud-
ing index test non-evaluable subjects (Model 4.1) will not lead to biased estimates of
sensitivity, specificity, LR+, LR− and AUC. Thus in practice, researchers can be confi-
dent to apply Model 4.1 when there is a belief in the MAR assumption. However, when
disease prevalence or PPV and NPV are of interest, excluding non-evaluable subjects
could lead to biased estimates of these parameters. Under this situation, the extended
TGLMM accounting for missingness should be preferred. Even though the extended
TGLMM is more theoretically complex than the widely used bivariate random effects
model, it is easy to program use SAS NLMIXED procedure. Model 4.2, Model 4.3 and
the intent-to-diagnose approach all largely under- or over- estimate sensitivity and speci-
ficity, so that they should not be recommended when MAR assumption is not seriously
violated.
Adequate reporting of the missing outcomes in study reports is essential to apply
the discussed models. As shown in the simulation studies, different missing scenarios
can have different impact on how estimates are biased and more importantly, missing
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mechanism can indicate whether the MAR assumption holds. When the MAR assump-
tion is violated, i.e., the probability of non-evaluation depends on unobserved index
test outcomes, the direction and magnitude of bias are hard to predict. Few sensitivity
analysis methods using pattern mixture models and selection models are available for
this scenario[81, 82]. These approaches can be explored in further research. On the
other hand, number of non-evaluable results need to be known in order to apply the
proposed methods. However, a recent study shows that they are not consistently or
adequately reported in published studies [83].
A reviewer has pointed out that as long as number of non-evaluable subjects are
known, disease prevalence can be estimated unbiasedly through an univariate meta-
analysis. Consequently, together with unbiased sensitivity and specificity estimates,
PPV and NPV estimates are unbiased too. This approach is a simpler method than the
proposed extended TGLMM to estimate prevalence, however, can be less efficient by
ignoring the potential correlation between prevalence, sensitivity and specificity, which
may result in wider confidence intervals.
For an individual patient, different approaches of treating a missing result can have
different impact. For example, if index test results are missing due to the same reason of
returning a negative result (and thus is MNAR), then treating such patients as disease
negatives can yield unbiased estimate of prevalence for a study, and also won’t affect
the patients’ diagnosis. On the contrary, if index test missing patients are treated as
positives for reasons such as suspicious of serious disease like cancer [84], it may result in
over-estimation of disease prevalence and unnecessary medial cost for the patient. For
another example, if index test is repeatable and repeated for subjects with non-evaluable
results, then it is appropriate to ignore missing results.
Chapter 5
A Bayesian Hierarchical Model
for Network Meta-analysis of
Diagnostic Tests
In this chapter, we extend our discussion from NMA to NMA-DT and develop a NMA-
DT framework from the perspective of missing data analysis to address the challenges
discussed in Section 1.2. The proposed framework is motivated from the literature on
network meta-analysis of randomized clinical trials (NMA-CT), which extends the scope
of traditional pairwise meta-analysis by synthesizing both direct and indirect compar-
isons of multiple treatments across randomized controlled trials [85, 86, 87, 88, 89, 90].
Specifically, we view studies using the randomized design and non-comparative design
as if they were designed using the multiple test comparison design, such that all subjects
in all studies were evaluated by all candidate tests and a gold-standard test. However,
most of the studies include only a subset of the whole set of tests. The test outcomes
from non-included tests must be considered as missing data. By simultaneously com-
paring all candidate tests and the gold standard, the proposed approach can make use
of all available information, allow for borrowing of information across studies, and rank
diagnostic tests through full posterior inferences. This effectively handles four critical
challenges in the traditional MA-DT [54, 91, 61, 8] by: 1) combining information from
studies with all three designs; 2) pooling both studies with or without a gold standard;
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3) allowing different sets of candidate tests in different studies, or different subsets of
subjects within a study; and 4) accounting for potential heterogeneity across studies,
due to differences in study populations, design and lab technical issues, or complex
correlation structures among multiple diagnostic tests.
In the rest of this chapter, we start by introduing two motivating case studies in Sec-
tion 5.1: a NMA of deep vein thrombosis tests, and a NMA of latent tuberculosis tests.
We then present the proposed NMA-DT model, and the Bayesian inference method in
Section 5.2 and apply the proposed method to the two motivating studies in Section
5.3. In Section 5.4, the performance of the proposed method is evaluated through sim-
ulation studies, and compared to the naive separate MA-DT approach. Finally, Section
5.5 provides a brief discussion.
5.1 Motivating studies
5.1.1 NMA of deep vein thrombosis (DVT) tests
DVT is developed when blood clots form in one or more deep veins of the human body.
If DVT is left untreated, the blood clot can cause a pulmonary embolus, and possibly
resulting in death [92]. Consequently, correct diagnosis of DVT plays an important
role in its early-detection and treatment. The gold standard diagnostic test for DVT,
contrast venography, is an invasive procedure and can introduce allergic reactions [93].
Therefore, ultrasonography is a commonly used surrogate test, because it is non-invasive
and has good accuracy. Alternatively, D-dimer is a small protein fragment present in
the blood when there is a blood clot, and thus testing its concentration can also be used
to diagnose DVT. Moreover, the test for D-dimer concentration can be easily performed
in a screening blood test. Several studies have shown that D-dimer has high sensitivity,
high negative predictive value (NPV), and moderate specificity [94].
A recent paper by Kang et al.[51] presented a meta-analysis that included 12 studies
comparing the accuracy of diagnostic tests for DVT. Among the 12 studies, four stud-
ies compared D-dimer test to venography, three studies compared ultrasonography to
venography, and five studies compared the D-dimer to ultrasonography [51]. None of the
studies compared the three tests together. Kang et al.[51] applied a mixed-effects log-
linear model, with random effects incorporated to account for the heterogeneity in test
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accuracies of D-dimer but not for ultrasonography. In addition, the log linear model for
test accuracies (e.g. sensitivity and specificity) made it difficult to interpret the model
parameters, and hard to generalize to comparing more tests.
5.1.2 NMA of latent tuberculosis (TB) tests
Tuberculosis is a fatal disease that causes two million deaths per year globally [95]. The
tuberculin skin test (TST) have been used to detect latent TB for many years, but has
been found to have low and highly variable specificity [48]. Two interferon-γ-release
assays, QuantiFERON-TB gold (QFG) and T-SPOT.TB (TSPOT), are now available,
and they are considered to be attractive alternative tests with operational advantages
and possibly increased specificity.
Sadatsafavi et al.[19] studied the performance of the three candidate tests for di-
agnosing latent TB, namely QFG, TSPOT and TST, through a meta-analysis of 22
studies. Among them, two studies compared the three tests on the same group of par-
ticipants, one study compared TSPOT to TST, and the rest of the studies compared
QFG to TST. Cross-tabulated results comparing the three tests or subsets of the three
tests were reported [19]. In this NMA-DT dataset, none of the studies included the gold
standard test and some studies compared three tests together. Sadatsafavi et al. [19]
used latent class random-effects models to account for varying test performances and
prevalences across studies, where only one random effect for sensitivity or specificity
of one of the tests can be included. In addition, potential correlations between disease
prevalence and the test accuracy parameters were not taken into account.
5.2 A unified statistical framework
We present a Bayesian hierarchical NMA-DT model to compare multiple tests simul-
taneously. In this paper, we focus on modeling a commonly used pair of test accuracy
indicies, Se and Sp, where sensitivity(Se) is the probability of a candidate test being
positive given a diseased subject, and specificity(Sp) is the probability of a candidate
test being negative given non-diseased status[1]. In addition, disease prevalence is also
modeled such that by estimating the overall prevalence, other test accuracy indicies
such as PPV and NPV can be calculated. In this section, we first present the model
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given the random effects, and then describe the distributions of the random effects and
prior distributions of the fixed effects.
5.2.1 Likelihood function
We view different studies as if they were all potentially designed to adopt a multiple test
comparison design, such that all studies should undergo a whole set of tests containing
all candidate tests and a gold-standard. However, each of the studies includes a subset of
the whole set, and the test outcomes from non-included tests are considered as missing
data [46]. We assume that the missing test outcomes are missing at random (MAR).
Under MAR, the presence of a test does not depend on any unobserved characteristics,
which in our case means that missingness is independent of sensitivity and specificity
[46].
Let T = {T0, T1, . . . , TK} be a set of K + 1 binary diagnostic tests, where T0 de-
notes the gold standard and T1, . . . , TK stand for the candidate tests under evaluation.
Suppose we have a collection of i = 1, . . . , N studies, where each reports outcomes of
tests in a subset of T . In the ith study, let yijk be the test outcome of Tk on subject
j (yijk = 1 if positive and 0 if negative), and let δijk be the missing data indicator
(δijk = 1 if Tk is conducted on the jth subject, and 0 if not). Let pii be the study-
specific disease prevalence: pii = P (yij0 = 1), i = 1, . . . , N . Let Seik and Spik denote
the study specific sensitivity and specificity for the kth test (k = 1, . . . ,K), respectively:
Seik = P (yijk = 1|yij0 = 1) and Spik = P (yijk = 0|yij0 = 0). Denote Kij as the set of
tests conducted on subject j in the ith study, and yij = {yijk : k ∈ Kij} be the collec-
tion of test outcomes for this subject. We note that yij can be equivalently written as
yij = {δijkyijk : k = 1, . . . ,K}.
To derive the likelihood for the jth subject in the ith study, first consider a subject
that is tested by the gold standard test (δij0 = 1) so that the true disease status
is known. Conditional independence is assumed such that candidate test results are
independent given disease status. This assumption has been widely used in latent class
models assessing accuracy of diagnostic tests without a gold standard [17, 18]. Thus,
the likelihood of the test outcomes for a diseased subject is given by
P (yij , yij0 = 1) = P (yij0 = 1)P (yij |yij0 = 1) = pii
∏
k∈Kij
(Seik)
yijk(1− Seik)(1−yijk) = piihij1,
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where hij1 =
∏
k∈Kij (Seik)
yijk(1− Seik)(1−yijk). Similarly, the likelihood for a non-
diseased subject j in study i is given by
P (yij , yij0 = 0) = P (yij0 = 0)P (yij |yij0 = 0) = (1−pii)
∏
k∈Kij
(Spik)
(1−yijk)(1− Spik)yijk = (1−pii)hij0,
where hij0 =
∏
k∈Kij (Spik)
(1−yijk)(1− Spik)yijk .
Second, for subject j who is not tested by the gold standard, the likelihood of the
test outcomes is given by
P (yij) = P (yij , yij0 = 1) + P (yij , yij0 = 0) = piihij1 + (1− pii)hij0.
In general, the likelihood of test outcomes for subject j (tested by the gold standard
or not, indicated by δij0) can be written as
P (yij) = (piihij1)
δij0yij0 [(1− pii)hij0]δij0(1−yij0)[piihij1 + (1− pii)hij0](1−δij0). (5.1)
5.2.2 Random effects and prior specifications
Multivariate random effects are used to account for potential across-study heterogeneities
in prevalence, sensitivities and specificities and correlations among them. Specifically,
we write
pii = Φ(η+ εi), Seik = Φ(αk +µik), and Spik = Φ(βk + νik), i = 1, . . . , N, k = 1, . . . ,K,
(5.2)
where Φ(·) is the standard normal cumulative distribution function for probit trans-
formations. The parameter η is the fixed effect for prevalence, and αk and βk are the
fixed effects for sensitivity and specificity of Tk, respectively. Median disease preva-
lence, sensitivity and specificity of Tk can be estimated as pi = Φ(η), Sek = Φ(αk) and
Spk = Φ(βk), respectively. The random effects εi, µik and νik are the study-specific
effects for prevalence, sensitivity and specificity of Tk, respectively. It is straightforward
to incorporate meta-regression covariates in equation (5.2) as
pii = Φ(η + η˜Xi + εi), Seik = Φ(αk + α˜W i + µik), Spik = Φ(βk + β˜Zi + νik),
for i = 1, . . . , N and k = 1, . . . ,K, where Xi, W i and Zi are study-level covariates such
as study population characteristics and η˜, α˜ and β˜ are the corresponding coefficient
vectors. In this paper, we focus on models without covariates for simplicity.
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We introduce the within-study dependency structure of multiple test parameters by
assuming that the random effect vector follows a multivariate normal distribution. Fur-
thermore, this distribution also accounts for potential correlations between prevalence
and the test accuracy parameters [21, 16]:
(εi, µi1, νi1, . . . , µiK , νiK)
T ∼MVN(0,Σ), i = 1, . . . , N.
The covariance matrix Σ can be written as Σ = SΩS, where S is a (2K+ 1)× (2K+ 1)
diagonal matrix with diagonal elements (σpi, σSe1 , σSp1 , . . . , σSeK , σSpK ) capturing the
between study heterogeneities, and Ω is a positive definite correlation matrix whose
diagonal elements are 1, and whose off-diagonal elements measure potential correlations
among disease prevalence and the test accuracy parameters. We assume the same
correlation structure for all studies (with missing tests or not). Therefore, studies
reporting all test outcomes of T contribute to estimating Σ, and studies with missing
test outcomes directly contribute to estimating a submatrix of Σ. Furthermore, missing
test accuracies can be predicted from Σ. By assuming MAR and the same covariance
matrix across all studies, which is equivalent to assuming all studies apply the multiple
test comparison design, the NMA-DT model can combine studies reporting different sets
of candidate tests and make correct inferences when comparing the test performances.
A conjugate Wishart prior is assumed for the precision matrix: Σ−1 ∼Wishart(R, v).
Taking the degrees of freedom v equal to the dimension of Σ, 2K + 1, will assign an
approximately uniform prior on the correlation coefficients. Different choices of R can
give relatively informative or non-informative priors on the variance parameters; specific
choices of R are discussed in the case studies. Non-informative normal priors (N(0, 10))
are assumed for η, αk and βk (k = 1, . . . ,K), which correspond to 95% prior credible
intervals (CI) of approximately (0,1) for pi, Sek and Spk, k = 1, . . . ,K.
5.2.3 Model implementation and a Bayesian ranking procedure
We use the JAGS software via the rjags package in R to sample from the joint posterior
distribution using Markov chain Monte Carlo (MCMC) methods [70, 96]. The posterior
samples are drawn by Gibbs and Metropolis-Hastings algorithms. Naturally, the pos-
terior estimates are similar to the MLEs when the priors are non-informative. On the
other hand, the Bayesian approach allows for full posterior inference, so that asymptotic
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approximations are not required. Posterior samples of median disease prevalence, sen-
sitivity and specificity of Tk can be achieved by transformation of the MCMC samples:
pi = Φ(η), Sek = Φ(αk) and Spk = Φ(βk). Posterior samples of PPV, NPV, LR+ and
LR− of Tk can also be obtained from the MCMC samples of sensitivities, specificities
and prevalences:
PPVik =
Seikpii
Seikpii + (1− Spik)(1− pii) , NPVik =
Spik(1− pii)
Spik(1− pii) + (1− Seik)pii ,
LR+ik =
Seik
1− Spik , and LR−ik =
1− Seik
Spik
.
In NMA-DT, the Bayesian approach can also facilitate ranking the tests using a
Bayesian ranking procedure based on the posterior samples. Specifically, the “best”
tests can be identified by calculating the posterior probability of Tk being among the
best C tests (not counting T0):
Pr(rank(Sek) ≤ C, rank(Spk) ≤ C|Data), C = 1, . . . ,K. (5.3)
5.2.4 A measure of inconsistency
The NMA-DT model relies on an important “consistency” assumption, which assumes
that candidate tests would have been performed consistently on subjects assigned and
not assigned to the test. However, inconsistency could occur, for example when, studies
that do not include T1 include a population for which T1 is inappropriate, and hence
whose performance may differ systematically from studies that do include T1. In this
situation, the MAR assumption is questionable, and borrowing information from stud-
ies that do not provide direct estimates of test accuracies must be done with caution.
The concern of inconsistency is also discussed in contrast-based NMA methods [86, 87],
wherein indirect evidence may be inconsistent with direct evidence. Lu and Ades [87]
proposed to use inconsistency degrees of freedom to estimate the degree of inconsis-
tency in evidence cycles. However, this method cannot be directly applied in NMA-DT
because iti is restricted to relative effects (e.g., log odds ratios), while NMA-DT esti-
mates marginal test accuracies (e.g., Se and Sp). A new measurement is proposed for
arm-based NMA methods [97].
For Tk, to measure inconsistency in sensitivity (specificity), we propose to calculate
the discrepancy between posterior study-specific sensitivity (specificity) estimates in
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observed studies and unobserved studies, i.e.,
ICSek =
∑
k∈Kij
Seik
/∑
I(k ∈ Kij)−
∑
k 6∈Kij
Seik
/∑
{1− I(k ∈ Kij)},
ICSpk =
∑
k∈Kij
Spik
/∑
I(k ∈ Kij)−
∑
k 6∈Kij
Spik
/∑
{1− I(k ∈ Kij)}, (5.4)
Posterior estimates of ICSek and IC
Sp
k can be calculated from MCMC posterior samples
and their 95% CIs can be used to assess whether they differ from 0, which would
indicate significantly inconsistent test performance between studies with and without
Tk outcomes.
5.3 Case study results and sensitivity analyses
5.3.1 NMA of DVT tests
We analyze the NMA of DVT tests in Section 5.1.1 by the proposed NMA-DT model.
In this study, we have K = 2. We adopt a moderately informative Wishart prior with
v = 5 and R with diagonal elements equal to 5 and off-diagonal elements equal to 0.05.
This Wishart prior corresponds to a 95% prior CI of (0.2, 15) for the standard deviation
components (σpi, σSe1 , σSp1 , σSe2 , σSp2). We fit the model by assuming vague N(0, 10)
priors for η, αk and βk.
After 10,000 burn-in samples, 1,000,000 posterior samples were obtained. Table 5.1
shows the results from the proposed NMA-DT model under the “all studies” column.
Figure 5.1 plots posterior distributions and study-specific posterior medians and 95% CIs
for the prevalence, sensitivity, and specificity parameters. We write posterior medians
followed by 95% CI in brackets for the rest of this paper. The NMA-DT model concludes
that ultrasonography has a median Se of 0.90 (0.77, 0.96) and a median Sp of 0.80 (0.54,
0.97). The D-dimer test is estimated to have moderate ability in diagnosing DVT, with
median Se 0.83 (0.68, 0.92) and median Sp 0.88 (0.75, 0.97). From equation (5.3),
the posterior probabilities of ultrasonography ranking first in terms of sensitivity is
0.84, and the D-dimer test ranking first in terms of specificity is 0.74. The posterior
probability that ultrasonography (D-dimer) ranks first in terms of both sensitivity and
specificity is 0.20 (0.13), respectively. Overall, ultrasonography is favored in detecting
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Table 5.1: Meta-analysis of DVT tests: median estimates and 95% CIs. Estimates from
models using all studies under “All studies” are compared to estimates excluding an
“outlier” study 5 under “Without outlier”.
All studies Without outlier
Prevalence 0.43 (0.36, 0.50) 0.43 (0.35, 0.51)
Ultrasonography
Sensitivity 0.90 (0.77, 0.96) 0.88 (0.74, 0.96)
Specificity 0.80 (0.54, 0.97) 0.83 (0.63, 0.97)
PPV 0.84 (0.68, 0.96) 0.80 (0.58, 0.96)
NPV 0.91 (0.80, 0.97) 0.90 (0.79, 0.97)
LR+ 4.39 (1.89, 27.90) 5.22 (2.19, 29.44)
LR− 0.13 (0.05, 0.33) 0.15 (0.05, 0.36)
D-dimer
Sensitivity 0.83 (0.68, 0.92) 0.82 (0.67, 0.91)
Specificity 0.88 (0.75, 0.97) 0.87 (0.75, 0.97)
PPV 0.84 (0.68 0.96) 0.83 (0.67, 0.96)
NPV 0.87 (0.77, 0.94) 0.86 (0.77, 0.93)
LR+ 7.00 (3.10, 33.49) 6.43 (3.04, 28.4)
LR− 0.20 (0.09, 0.38) 0.22 (0.10, 0.40)
disease status with higher sensitivity, whereas D-dimer performs better in ruling out
the non-diseased with higher specificity. The posterior inconsistency measurements are
0.13 (−0.06, 0.45), 0.04 (−0.06, 0.34), 0.06 (−0.12, 0.42) and 0.07 (−0.2, 0.45) for D-
dimer Se, ultrasonography Se, D-dimer Sp and ultrasonography Sp, respectively. None
of these measurements suggest the presence of significant inconsistency.
Sensitivity analyses to prior distribution on Σ−1
Sensitivity analyses to the prior distributions on Σ−1 were conducted to evaluate the
effect of the prior distribution on the posterior prevalence, sensitivity and specificity. A
relatively informative Wishart prior with v = 5 andR having diagonal elements equal to
20 and off-diagonal elements equal to 0.05 is used in this repeat analysis. This Wishart
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Figure 5.1: Meta-analysis of DVT tests: posterior densities and study-specific posterior es-
timates. The left column plots posterior densities and the right column plots study-specific
posterior medians and their 95% CIs for prevalence, sensitivities and specificities of ultrasonog-
raphy and D-dimer tests. Circles represent study-specific posterior medians and solid and dashed
lines denote the corresponding 95% CIs when the test is included in the study and not included
(imputed by MCMC sampling), respectively. A red line indicates a potential outlier study.
Dotted lines indicate overall posterior medians across studies.
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prior corresponds to a 95% prior CI of (0.1, 7.5) for the standard deviation components
(σpi, σSe1 , σSp1 , σSe2 , σSp2). The posterior median disease prevalence is estimated to be
0.43 (0.37, 0.49). Ultrasonography has posterior median sensitivity 0.89 (0.78, 0.96)
and specificity 0.79 (0.54, 0.96). The D-dimer test has posterior median sensitivity 0.82
(0.67, 0.92) and specificity 0.88 (0.75, 0.97). Similar posterior medians and 95% CIs
compared to Table 1 are derived using a more informative prior.
A vague prior taking v = 5 and R having diagonal elements equal to 1 and off-
diagonal elements equal to 0.05 is also used to repeat the analysis. This prior distribution
corresponds to a 95% prior CI of (0.4, 35) for the standard deviation components.
The posterior median of disease prevalence is 0.43 (0.33, 0.53). Ultrasonography has
posterior median sensitivity 0.90 (0.74, 0.97) and specificity 0.82 (0.56, 0.98). D-dimer
has posterior median sensitivity 0.83 (0.65, 0.93) and specificity of 0.89 (0.74, 0.98).
Compared to Table 5.1, this prior leads to wider CIs for all parameters and slightly
higher posterior medians for ultrasonography Sp.
Overall, different choices of the Wishart prior for Σ−1 have little effect on the pos-
terior medians of prevalence, sensitivity and specificity, but have modest influences on
the width of their CIs.
Sensitivity analysis to an “outlier” study
In the right column of Figure 5.1, heterogeneity is observed in the posterior estimates
across studies. For example, Study 5 has an extremely low estimate of ultrasonogra-
phy Sp (red), suggesting that it may be an “outlier” study. Thus, to investigate the
implications of a potential outlier, we repeat the analysis excluding Study 5. Table
5.1 summarizes the posterior estimates under column “without outlier”. Compared to
the analysis using all studies, when Study 5 is excluded, the estimate of ultrasonogra-
phy specificity is increased from 0.80 (0.54, 0.97) to 0.83 (0.63, 0.97) and the posterior
median sensitivity is lowered from 0.90 (0.77, 0.96) to 0.88 (0.74, 0.96). As a result,
estimates of PPV and LR+ of ultrasonography are also changed. Estimates of disease
prevalence and D-dimer sensitivity and specificity remain similar to the estimates using
all studies. This is because Study 5 compares ultrasonography to the gold standard, so
that the estimates of D-dimer accuracy are not directly affected when it is excluded.
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Sensitivity analysis to the MAR assumption
The NMA-DT model is built upon the assumption of MAR. However, in practice, non-
random missingness (MNAR) can happen when, for example, researchers select candi-
date tests that are believed to have better performance, and hence missing test out-
comes are related to unknown test accuracy parameters. In this subsection, we conduct
a sensitivity analysis to explore the influence on parameter estimates when the MAR
assumption is violated. Let the N ×K matrix M denote the study-level missingness of
a NMA-DT dataset containing N studies and K candidate tests. The entries of M are
mik, for i = 1, . . . , N and k = 1, . . . ,K, such that mik = 1 if Tk is missing in study i and
mik = 0 otherwise. Bernoulli distributions are assumed for the missingness indicators:
mik ∼ Ber(pik), where pik is the probability of a missing Tk in study i. We specify a
model of missingness for pik as logit(pik) = γk + γ1k × logit(Seik) + γ0k × logit(Spik),
where γ1k (γ0k) controls the degree of association between the missing outcomes and the
study-specific sensitivity (specificity). We assume non-positive γ1k and γ0k such that Tk
is prone to be missing when its accuracy is low. When γ1k = 0 (γ0k = 0), the outcomes
of Tk are MAR with respect to its sensitivity (specificity). We incorporate the model
of missingness in the likelihood in (5.1) under different values of γ1k and γ0k: 0, −1
and −2, which correspond to MAR, and an odds ratio of missingness of 0.37 and 0.13,
respectively (with respect to 1 unit increase in the logit scale of accuracy parameters).
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Table 5.2: Meta-analysis of DVT tests: median parameter estimates and 95% CIs under different missingness assump-
tions.
MNAR γ11 γ12 γ01 γ02 pi Se: D-dimer Se: ultrasonography Sp: D-dimer Sp: ultrasonography
None 0 0 0 0 0.43 (0.36,0.50) 0.83 (0.68,0.92) 0.90 (0.77,0.96) 0.88 (0.75,0.97) 0.80 (0.54,0.97)
D-dimer -1 0 -1 0 0.44 (0.37,0.51) 0.78 (0.49,0.94) 0.95 (0.85,1) 0.80 (0.45,0.96) 0.83 (0.60, 1)
Ultrasonography 0 -1 0 -1 0.43 (0.36,0.50) 0.91 (0.78,1) 0.88 (0.64,0.98) 0.92 (0.79,1) 0.54 (0.11,0.89)
Se -1 -1 0 0 0.43 (0.37,0.51) 0.84 (0.63,0.96) 0.89 (0.63,0.99) 0.90 (0.77,0.99) 0.79 (0.51,0.99)
Sp 0 0 -1 -1 0.43 (0.36,0.51) 0.86 (0.69,0.98) 0.93 (0.83,0.99) 0.86 (0.63,0.98) 0.70 (0.37,0.92)
All -1 -1 -1 -1 0.44 (0.37,0.51) 0.85 (0.68,0.96) 0.90 (0.78,0.98) 0.87 (0.72,0.98) 0.71 (0.38,0.91)
D-dimer -2 0 -2 0 0.44 (0.37,0.52) 0.77 (0.46,0.93) 0.95 (0.85,1) 0.81 (0.49,0.96) 0.85 (0.62,1)
Ultrasonography 0 -2 0 -2 0.43 (0.36,0.50) 0.91 (0.77,1) 0.87 (0.56,0.99) 0.92 (0.79,1) 0.53 (0.11, 0.87)
Se -2 -2 0 0 0.44 (0.37, 0.52) 0.81 (0.56, 0.94) 0.84 (0.53, 0.97) 0.93 (0.81, 0.99) 0.83 (0.57, 0.98)
Sp 0 0 -2 -2 0.43 (0.36,0.51) 0.88 (00.74,0.98) 0.96 (0.86,1) 0.83 (0.61,0.96) 0.68 (0.38,0.89)
All -2 -2 -2 -2 0.44 (0.37,0.51) 0.82 (0.55,0.96) 0.88 (0.65,0.98) 0.86 (0.58,0.99) 0.69 (0.25,0.92)
MNAR=“None” is equivalent to MAR; MNAR=“D-dimer” (“Ultrasonography”) means missingness related to sen-
sitivity and specificity of D-dimer test (ultrasonography); MNAR=“Se”(“Sp”) means missingness related to the
sensitivities (specificities) of both the D-dimer test and ultrasonography; MNAR=“All” means missingness related
to sensitivities and specificities of both tests. Bold numbers indicate parameters directly related to missingness.
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The posterior medians of prevalence, sensitivity and specificity are presented in Ta-
ble 5.2 under different missingness assumptions: MAR, missingness related to accuracy
of ultrasonography or D-dimer test only, missingness related to sensitivities of both
tests or specificities only, and missingness related to sensitivities and specificities of
both tests. Compared to MAR, the estimates of pi are barely affected under our dif-
ferent assumptions. When the missingness probabilities are negatively correlated with
one of the tests only, the posterior estimates of Se and Sp are lower while the accuracy
estimates of the other tests are higher due to the correlation structure between the test
accuracy parameters. For example, when γ11 = γ01 = −1, the posterior estimate of D-
dimer Se is 0.78 compared to 0.83 under MAR, and Sp is 0.80 compared to 0.88 under
MAR, while the ultrasonography Se is 0.95 compared to 0.90 under MAR and Sp is
0.83 compared to 0.80 under MAR. When the missingness probabilities are negatively
correlated with sensitivities, the estimate of D-dimer Se is slightly higher, whereas the
estimate of ultrasonography Se is slightly lower. When the missingness probabilities are
negatively correlated with specificities, specificity estimates of D-dimer and ultrasonog-
raphy are both lower than the estimates under MAR. When the missing probabilities are
negatively correlated with sensitivities and specificities of both tests, assuming MAR
generally provides higher estimates of the test accuracies (except for sensitivity esti-
mates when γ1k = γ0k = −1, k = 1, 2). The differences between the estimates under the
MAR and MNAR assumptions are generally enlarged when γ1k = γ0k = −2, k = 1, 2,
than when they take values of −1. In general, when missingness is negatively correlated
with the test accuracy parameters, ignoring the model of missingness will overestimate
test performance. Note that, as shown in this example, due to the complex dependency
structure of multiple test parameters, it is hard to tell whether the other tests will be
over- or under-estimated when one of the tests must cope with MNAR.
5.3.2 NMA of latent TB tests
The meta-analysis of latent TB studies in Sadatasfavi et al.[19] is re-analyzed by the
proposed NMA-DT model. We use a Wishart prior with v = 7 (K=3) and R having
diagonal elements equal to 5 and off diagonal elements equal to 0.05, which corresponds
to a 95% prior CI of (0.2, 17) for the standard deviations. The same priors as in
Section 5.3.1 are used for η, αk and βk. 1,000,000 MCMC samples were collected after
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Table 5.3: Meta-analysis of latent TB tests: posterior medians and 95% CI’s
Parameter Median (95% CI) Median (95% CI) Median (95% CI)
Prevalence 0.31 (0.16, 0.49)
QFG TSPOT TST
Sensitivity 0.58 (0.38, 0.82) 0.74 (0.41, 0.94) 0.85 (0.73, 0.94)
Specificity 0.99 (0.95, 1) 0.91 (0.62, 0.99) 0.96 (0.78, 1)
PPV 0.96 (0.81, 1) 0.82 (0.39, 0.99) 0.93 (0.50, 1)
NPV 0.84 (0.67, 0.96) 0.89 (0.69, 0.98) 0.93 (0.86, 0.98)
LR+ 49.5 (12.4, 830.2) 10.2 (1.7, 164.8) 28.2 (3.7, 944.9)
LR- 0.42 (0.18, 0.63) 0.29 (0.07, 0.71) 0.16 (0.06, 0.29)
10,000 burn-in samples. The posterior estimates are summarized in Table 5.3, with
marginal posterior density estimates are plotted in Figure 5.2, panel A. The overall
disease prevalence posterior median is 0.31 (0.16, 0.49). Comparing the three tests,
TST has highest sensitivity of 0.85 (0.73, 0.94) and specificity of 0.97 (0.77, 1). TSPOT
has sensitivity of 0.74 (0.41, 0.94) and the lowest specificity, 0.93 (0.63, 1). QFG has
the lowest sensitivity, 0.58 (0.38, 0.82), but the highest specificity, 0.99 (0.95, 1). The
posterior probabilities of the TST, TSPOT and QFG test ranking first are 0.78, 0.2 and
0.02 in terms of sensitivity, and 0.29, 0.06 and 0.65 in terms of specificity, respectively.
Therefore, the results suggest that the TST outperforms the other two tests considering
sensitivity, and QFG performs the best in terms of specificity. Inconsistency estimates
are −0.35 (−0.53, 0.15), 0.16 (−0.17, 0.58), 0.01 (−0.04, 0.19) and 0.01 (−0.10, 0.48) for
QFG Se, TSPOT Se, QFG Sp and TSPOT Sp, respectively. Significant inconsistency
is not detected in these estimates.
Sensitivity analyses to prior distributions of Σ−1
Sensitivity analyses to the prior distribution of Σ−1 are also considered to evaluate the
effect of the prior distribution on the posterior estimates of prevalence, sensitivity and
specificity. Compared with Table 5.3, when the Wishart prior takes R with diagonal
elements equal to 20 and off-diagonal elements equal to 0.05, the TSPOT test and TST
have lower Sp estimates: 0.87 (0.56, 0.99) and 0.93 (0.71, 1), respectively. Estimates of
prevalence and other sensitivities and specificites are close to those in Table 5.3. When
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Figure 5.2: Meta-analysis of latent TB tests: panel A plots the posterior densities of
parameters using all studies; Panel B plots the posterior densities when studies reporting
the TSPOT test are excluded.
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the Wishart prior takes R with diagonal elements equal to 1 and off-diagonal elements
equal to 0.05, similar posterior medians and CIs as in Table 5.3 are obtained.
Sensitivity analysis to TSPOT test
In Figure 5.2 panel A, the posterior densities of TSPOT sensitivity and specificity are
relatively flat compared to the other two tests. This can be explained by the fact that
only three out of 22 studies report TSPOT meaning there is not much information about
TSPOT in these NMA-DT data. We therefore exclude the three studies with TSPOT
(two comparing all tests and one comparing TSPOT to TST) to examine whether
the exclusion of an individual candidate test affects the results of an NMA-DT. The
posterior densities of the QFG and TST tests after excluding studies reporting TSPOT
are presented in panel B of Figure 5.2. Posterior median disease prevalence is estimated
as 0.36 (0.14, 0.58). Compared to the estimates from Table 5.3, the TST test is estimated
to have a higher sensitivity of 0.88 (0.78, 0.96) but a lower specificity of 0.91 (0.63, 0.99).
The QFG test has a slightly lower estimate of sensitivity of 0.56 (0.32, 0.88), and the
same estimate of specificity of 0.99 (0.96, 1). The probabilities of the TST and QFG
test ranking first are 0.96 and 0.04 in terms of sensitivity, and 0.09 and 0.91 in terms
of specificity, respectively. The inference about TST is affected more by the exclusion
of the TSPOT test than the QFG test. This is an interesting observation, indicating
that excluding one of the tests, i.e., ignoring the correlation structure among all tests,
could have nontrivial effects on the accuracy of the estimates of the other tests. Similar
conclusions are made in Mills et al., in which excluding treatments in NMA can have
substantial changes of other treatment effect estimates [98]. Therefore, it is important
to account for such correlations, and to combine information from all available studies
in NMA-DT.
Sensitivity analysis to the MAR assumption
The model of missingness in Section 5.3.1 is fitted to the latent TB data to explore the
influence on the posterior estimates under MNAR. Again, non-positive γ1k and γ0k are
used so that Tk is prone to be missing when its accuracy is low and γ1k and γ0k can
take values 0 or −1. The posterior medians of prevalence, sensitivity and specificity
are presented in Table 5.4 under different missingness assumptions: MAR, missingness
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Table 5.4: Meta-analysis of latent TB tests: posterior estimates under different miss-
ingness assumptions.
MNAR None Se Sp TSPOT
Parameter Median (95% CI) Median (95% CI) Median (95% CI) Median (95% CI)
Prevalence 0.31 (0.16,0.49) 0.36 (0.06,0.6) 0.37 (0.18,0.6) 0.31 (0.15,0.53)
Se: QFG 0.58 (0.38,0.82) 0.47 (0.29,0.99) 0.53 (0.28,1) 0.56 (0.38,0.96)
Se: TSPOT 0.74 (0.41,0.94) 0 (0,0.36) 0.99 (0.06,1) 0 (0,0.72)
Se: TST 0.85 (0.73,0.94) 0.86 (0.74,1) 0.84 (0.71,0.94) 0.89 (0.74,1)
Sp: QFG 0.99 (0.91,1) 1 (0.95,1) 1 (0.98,1) 0.98 (0.94,1)
Sp: TSPOT 0.91 (0.62,0.99) 0.87 (0.01,1) 0.04 (0,0.34) 0.86 (0,1)
Sp: TST 0.96 (0.78,1) 1 (0.7,1) 1 (0.81,1) 1 (0.81,1)
MNAR=“None” is equivalent to MAR; MNAR=“Se”(“Sp”) means missingness re-
lated to the sensitivities (specificities) of all tests; MNAR=“TSPOT” means miss-
ingness related to sensitivity and specificity of TSPOT test. Bold numbers indicate
parameters directly related to missingness.
related to sensitivities of all three tests, missingness related to specificities of all tests,
and missingness related to the TSPOT test only.
When MNAR is assumed for sensitivities, the QFG and TSPOT tests have lower
posterior sensitivity estimates, where the sensitivity of the TSPOT test is estimated
to be 0. Intuitively, because TSPOT is missing in 19 out of the 22 studies, it has a
high missingness probability, and thus should have low sensitivity if assuming that a
test is likely to be missing when it has bad performance (negative values of γ1k in this
case). For the same reason, when MNAR is assumed for specificities, the TSPOT test
has specificity estimated as 0.04. When MNAR is assumed for the TSPOT test, its
sensitivity is estimated to be 0 and its specificity as 0.86, both lower than the estimates
under MAR.
5.4 Simulation Studies
5.4.1 Simulation setups
Simulation studies were conducted to test how the NMA-DT model performs under
different assumptions. We assume K=2, i.e., the whole test set contains two candidate
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tests (T1 and T2) and a gold standard (T0). The Se (Sp) of T1 is 0.8 (0.9) and the Se
(Sp) of T2 is 0.6 (0.7); the overall true disease prevalence is 0.4. We assume the random
effects have standard deviations of 0.3: (σpi, σSe1 , σSp1 , . . . , σSeK , σSpK ) = 0.3. We test
the model performance under different assumptions on the magnitude of the correla-
tions on the probit-transformed parameters: weak (0.3), medium(0.5) or strong (0.8)
positive correlations between prevalence and sensitivities and negative correlations be-
tween prevalence and specificities and between sensitivies and specificities. Under each
scenario, we simulate 1000 replicates of NMA-DT datasets. Each dataset comprises 20
studies where 100 subjects are tested by both candidate tests and the gold standard. To
generate test outcomes in each study, study specific prevalences, sensitivities and speci-
ficities are sampled from the multivariate normal distribution of the probit transformed
parameters in Section 5.2, with the mean vector and covariance matrix specified above.
For each subject, test outcomes are generated according to the likelihood equation (5.1).
Finally, missingness indicators for each of the three tests are assigned such that the first
five studies do not have a missing test outcome, the next five studies are missing T1,
the next five are missing T2, and the last five studies are missing T0. Cross-classified
cell counts can be collected for each study to present the observed data as in the case
studies. Each simulated dataset is fitted by the proposed NMA-DT method.
We compare the performance of the NMA-DT model with a “naive” approach. The
“naive” method applies the trivariate generalized linear mixed model (TGLMM) [16] to
studies reporting both T1 and T0, accounting for potential correlations between disease
prevalence and test accuracy parameters. Specifically, studies reporting T1 and T2 and
studies reporting T2 and T0 are excluded from the naive analysis. Test outcomes of T2
in studies reporting all three tests are ignored, and only 2 × 2 tables cross-classifying
outcomes of T1 and T0 are used to fit the trivariate GLMM. In total, 10 out of the
20 studies in each dataset are used to evaluate the performance of T1 in the “naive”
approach. The estimates of the fixed effects for prevalence, sensitivity and specificity of
T1 are compared with the estimates from the NMA-DT model. The “naive” analysis is
not applied to T2 because T1 and T2 are exchangeable.
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5.4.2 Simulation results
Table 5.5 summarizes the bias, mean squared error (MSE) and 95% CI coverage proba-
bility (CP) of the fixed effects estimates using the proposed NMA-DT model (in column
“NMA-DT”). Under different correlation assumptions, the NMA-DT model is shown to
provide nearly unbiased estimates for all parameters with small MSE. Generally, as the
correlation becomes stronger, the estimates are more biased. For example, the estimate
of β1 is biased by 0.02 when there are strong correlations. The coverage probabilities
remain close to the nominal level of 0.95 when there is weak or medium correlation, and
increase to around 0.97 when there is strong correlation.
The fixed effect estimates for prevalence, sensitivity and specificity for T1 from the
“naive” approach are also summarized in Table 5.5, column “Naive”. Comparing the
two models, this approach provides generally larger bias and consistantly larger MSE
than the NMA-DT approach. This suggests that the NMA-DT model is less biased and
more efficient than the “naive” approach. It provides evidence that the NMA-DT model
gains efficiency by combing information from more studies and by taking into account
the correlation structure. Moreover, when there are weak or strong correlations, the
“naive” approach has large CPs and are greater than 0.97. Overall, the NMA-DT
model is shown to outperform the “naive” approach.
5.5 Discussion
There is a growing interest in simultaneously comparing the performance of multiple
diagnostic tests in a meta-analysis. However, due to the mixture of different study de-
signs, the variety of reported test outcomes across studies, the inherent heterogeneity
in a meta-analysis, and the complex correlation structure of multiple test outcomes on
the same individuals, the methodological development for NMA-DT remains challeng-
ing. In this chapter, we presented a Bayesian hierarchical NMA-DT framework that
addresses these challenges. An important feature of this proposed framework is that it
unifies all three types of study designs into the multiple test comparison design using a
missing data framework. In addition, the proposed framework can provide ranks of di-
agnostic tests, which can be used to guide clinical decision making. Through simulation
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Table 5.5: Simulation results: bias, mean square error (MSE) and 95% CI coverage
probabilities (CP) of the estimates for fixed effects η, α1, β1, α2, β2. Estimates from the
proposed NMA-DT model and the “naive” method are compared for T1.
NMA-DT Naive
Parameter (true) Bias MSE CP Bias MSE CP
Weak Correlation
η (-0.25) 0.001 0.008 0.957 0.001 0.011 0.976
α1 (0.84) 0.005 0.015 0.965 0.008 0.017 0.975
β1 (1.28) -0.001 0.013 0.966 0.003 0.015 0.978
α2 (0.25) 0.006 0.012 0.963
β2 (0.52) 0.003 0.01 0.966
Medium Correlation
η (-0.25) 0.001 0.005 0.967 0.001 0.011 0.962
α1 (0.84) 0.008 0.014 0.961 0.011 0.017 0.956
β1 (1.28) 0.008 0.014 0.957 0.013 0.017 0.958
α2 (0.25) 0.007 0.01 0.955
β2 (0.52) 0.007 0.009 0.959
Strong Correlation
η (-0.25) -0.006 0.007 0.964 -0.005 0.011 0.972
α1 (0.84) 0.01 0.013 0.972 0.014 0.016 0.973
β1 (1.28) 0.021 0.014 0.972 0.023 0.016 0.971
α2 (0.25) 0.007 0.011 0.971
β2 (0.52) 0.01 0.01 0.969
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studies, we have shown that the proposed NMA-DT method can provide unbiased esti-
mates for overall prevalence, test sensitivities, and specificities. In addition, it is more
efficient than a commonly used “naive” approach, in which separate meta-analyses are
implemented to evaluate one candidate test at a time.
The importance of checking the evidence consistency assumption was discussed.
However, current inconsistency measures in NMA-CT, such as the inconsistency degrees
of freedom [87] and the use of consistency equations [99, 100], cannot be directly applied
in NMA-DT because they are built upon relative effects. In this paper, we proposed to
measure inconsistency by computing the mean difference between posterior estimates
from studies reporting and not reporting a specific test. This measurement may suffer
from insufficient power when study sample sizes are small. Further research shall focus
on developing a formal test out of this measurement, and validate its power.
Another critical assumption is independent test results within each disease class.
In traditional MA-DT, this assumption is required under non-gold standard situations
where latent class models are used [18]. However, conditional dependence can exist,
such as when two candidate tests are based on a similar biological phenomeno. Several
methods have been developed to adjust for this dependence either through a correlation
parameter [18], an additional latent class random effect [101], or using multivariate
probit models [102]. However, they cannot be directly applied to our NMA-DT model,
because correlation parameters are suitable only for pairwise comparisons, and only a
small portion of the studies utilizing three different kinds of designs may be subject to
conditional dependence. Specifically, for studies adopting the randomized design, each
candidate test is compared to the gold standard, thus the conditional independence
assumption is not required. For studies adopting the multiple test comparison design,
conditional dependence may only become a concern when a gold-standard test is missing.
For similar reasons, non-comparative designs may be subject to conditional dependence
when a gold-standard test is not involved, and subjects are tested by multiple candidate
tests. As a result, how to adjust for conditional dependence in NMA-DT is a subject
for future studies.
A concern brought by combining studies in a systematic review is how to correctly
measure between-study heterogeneity, which plays an important role in choosing the
appropriate statistical model (i.e., fixed versus random effects model). In this chapter,
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as well as in some of the “classic” random effects meta-analysis methods, generalized
linear mixed models were used to account for heterogeneity in a Bayesian framework.
The posterior estimates of the covariance matrix for the random effects can provide some
information on the extent of heterogeneity. An inverse Wishart prior is often used for
the covariance matrix, but is limited in that the posterior variance components are then
always positive [103]. Another limitation brought by the inverse Wishart prior is that
when the correlation matrix grows, it imposes an unstructured covariance matrix while
a structured correlation assumption may be preferred to improve estimation and con-
vergence. Several attampts have been made to find alternative priors for the covariance
matrix [104, 71, 103], and their application in NMA-DT merits further research.
Chapter 6
Conclusions
6.1 Summary of major findings
This thesis explored novel statistical methods in the context of meta-analysis and net-
work meta-analysis of diagnostic tests. Our contribution lies in improving accuracy and
efficiency in evaluating diagnostic tests, which ultimately enable better decision-making
for patients, health practitioners and policy makers. In practice, this thesis serves as
a practical guide on how to better evaluate diagnostic test performance by presenting
detailed examples. Most importantly, the application of our novel NMA-DT methods
can be broadly applied in summarizing clinical trials related to diagnosing various dis-
eases. Health care decision makers can be better informed from this method than from
the traditional MA-DT, as they will now be able to rank each test and estimate the
probabilities of being the best diagnostic test.
In Chapter 2, we provided a systematic review of both traditional and advanced
models in MA-DT, for settings with and without a gold standard. We made careful
comparisons and summarizations of different methods, and gave recommendations for
their application in practice.
After reviewing current development in MA-DT, Chapter 3 tackled some of the
remaining limitations. We proposed a novel Bayesian hybrid GLMM that addressed
two important problems at the same time: combining case-control and cohort studies
in one meta-analysis; and adjusting for partial verification bias. We evaluated and
compared its performance with the current method, and illustrated its application using
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two interesting case studies. This method fills in the gap of correctly dealing with partial
verification in meta-analysis settings and allowing for utilization of much information
as possible from combing different study designs.
In Chapter 4, we then investiagated the challenge of accounting for non-evaluable
subjects. Built upon the TGLMM [16] approach, we proposed an extended TGLMM
method to account for this. Furthermore, we discovered that some current approaches
and conclusions in the literature can be misleading, and conducted simulation studies
to compare the performance of the proposed method. Simulation findings support the
extended TGLMM in that they give unbiased estimates of sensitivity and specificity, as
well as prevalence and other prevalence related accuracy indices (NPV and PPV). Also,
recommendations were made to aid readers in choosing appropriate models in practice.
Finally, in Chapter 5 we proceeded from MA-DT to NMA-DT, where the topic was
extended from evaluating a single candidate test to simultaneously evaluating multiple
candidate tests. We developed a missing data framework and a Bayesian hierarchical
model that offers important advantages over the traditional MA-DT: 1) it combines
studies using all three designs; 2) it pools both studies with and without a gold standard;
3) it combines studies with different sets of candidate tests; and 4) it accounts for
heterogeneity across studies and complex correlation structure among multiple tests.
We provided two examples to illustrate the proposed model, with discussion of the
MAR assumption, effect of outlying studies, choice of prior for covariance matrix etc.
Our work broadens the scope of meta-analysis of diagnostic tests from single test to
comparison of multiple tests, addressing the keen need of cost-effectiveness research
generated from the exploding number of available diagnostic instruments for a disease
condition.
6.2 Limitations and extensions to future work
Limitations remain that suggest future work. The hybrid GLMM in Chapter 3 and
extended TGLMM in Chapter 4 both rely on the assumption of MAR, as well as the main
model of NMA-DT in Chapter 5. We considered MNAR situations in the discussion
sections of these chapters, and presented models of missingness to adjust for MNAR as
sensitivity studies in the two examples in Chapter 5. We can take a closer look at MNAR
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situations in future research. Another limitation is the choice of priors for covariance
matrices. In Bayesian multivariate GLMMs (Chapter 3 and 5), Wishart priors were used
for the covariance matrices to ensure positive definite matrices. However, this approach
has some limitations. On the one hand, the choice of parameters for the Wishart prior
needs more discussion. We attempted to study the effect of prior selection on posterior
estimates through scaled Wishart priors and sensitivity analysis. Further studies can
focus on conducting simulation studies to systematically compare these effects. On the
other hand, more importantly, this issue is closely related to estimating the degree of
heterogeneity in MA-DT and NMA-DT. All the random effects models introduced in
this thesis aim at explaining heterogeneous performance of tests across studies, thus
correctly estimating the extent of this heterogeneity can justify our choice of random
effects models over fixed effects model. Wishart prior is limited in that the posterior
variance components are always positive, which restricted the development of a test for
zero variances. Application of alternative priors deserves future study. For NMA-DT,
evidence inconsistency can become an important concern when applying the proposed
model. We proposed a measurement of inconsistency in Chapter 5. Based on this
measurement, we can proceed to develop a formal test and validate its power.
This thesis motivates some interesting practical topics as well. First of all, to help
researchers applying the proposed approaches, developing computation software, such
as an R package, can ease the application of the models. Second, to step outside
the diagnostic test framework, potential applications can be meta-analysis of safety
studies in clinical research, where limited safety data in single studies can be combined
across studies. The correlation between toxicity and efficacy estimates shares some
similarity in the correlation between accuracy indices of diagnostic tests. Last but not
least, the hybrid GLMM and the Bayesian NMA-DT model both incorporate the idea of
combing different study designs in one meta-analysis, which can be potentially extended
to combing information observational studies and from randomized clinical trials.
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Table A.1: Data for the meta-analysis of gadolinium-enhanced MRI in detecting lymph
node metastases
ID Study n11 n01 n10 n00 n1m n0m
Cohort Studies
1 Bley, 2005 7 3 3 6 0 0
2 Drew, 1999 7 5 5 12 0 0
3 Gaa, 1999 18 6 3 19 0 0
4 Hasegawa, 2003 11 1 4 14 0 0
5 Kang, 2000 9 5 3 29 0 0
6 Kaza, 2006a 3 2 1 9 1 7
7 Krupski, 2002 6 0 2 7 0 0
8 Kvistad, 2000 15 9 8 33 0 0
9 Low, 2003 15 7 1 25 0 0
10 Wallengren, 1996ab 2 1 0 7 2 0
11 Einspieler, 1991a 5 1 2 3 9 4
12 Hawighorst, 1998 13 6 3 11 0 0
13 Hallscheidt, 1998a 7 1 1 23 NA NA
14 Luciani, 2004 7 1 1 7 0 0
15 Sheu, 2001ab 9 2 4 26 38 0
16 Manfredi, 2004ab 1 1 1 18 16 0
17 Murray, 2002 10 0 17 20 0 0
18 Okizuka, 1996 10 5 3 14 0 0
19 Oellinger, 2000 5 8 2 17 0 0
20 Rockall, 2007a 4 5 1 40 23 23
21 Barentsz, 1996 12 2 2 41 0 0
22 Ramsay, 2004ab 2 5 2 7 9 0
23 Hunerbein, 2000 3 1 1 22 0 0
24 Matsuoka, 2003 5 2 0 12 0 0
25 Thurnher, 1991a 6 3 1 11 NA NA
26 Mumtaz, 1997 36 4 6 29 0 0
Case-control Studies
27 Heuck, 1997 16 2 2 22 NA NA
28 Kim, 2000 91 16 65 45 NA NA
29 Vorreuther, 1990 4 0 1 31 NA NA
30 Tempany, 2000 5 8 25 133 NA NA
31 Matsuoka, 2004 18 6 8 22 NA NA
32 Medl, 1995 6 6 1 16 NA NA
a: The study has partial verification.
b: The numbers of n1m and n0m are arbitrarily assigned such that n0m = 0.
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Table A.2: Data for the meta-analysis of FDG PET in characterizing adrenal masses
ID Study n11 n01 n10 n00 n1m n0m
Cohort Studies
1 Groussin, 2009a 22 5 0 38 0 12
2 Brady, 2009a 36 36 36 44 0 92
3 Boland, 2009a 14 0 0 10 0 32
4 Vikram, 2008 25 12 5 70 0 0
5 Tessonnier, 2008ab 12 0 0 29 0 0
6 Sung, 2008a 26 7 8 19 0 1
7 Okada, 2008ab 16 0 3 16 0 0
8 Park, 2007ab 7 3 1 9 0 0
9 Han, 2007a 60 7 4 34 0 75
10 Caoili, 2007ab 10 5 1 43 0 0
11 Jana, 2006ab 28 2 2 48 0 12
12 Blake, 2006ab 9 2 0 30 0 0
13 Metser, 2005a 67 8 1 99 0 7
14 Zettinig, 2004ab 3 0 0 13 0 0
15 Kumar, 2004ab 67 4 5 37 0 0
16 Frilling, 2004 31 2 0 11 0 0
17 Yun, 2001ab 18 2 0 30 0 0
18 Maurea, 2001 13 0 0 10 0 0
19 Gupta, 2001ab 21 1 1 11 0 0
20 Erasmus, 1997ab 23 2 0 8 0 0
21 Boland, 1995a 14 0 0 10 0 32
a: The study has partial verification.
b: Failed to extract missing counts.
Appendix B
Additional simulation results for
hybrid GLMM
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Table B.1: Summary of 2000 simulations with data generated from settings with 30
studies and true Se (Sp)=0.9 (0.95).
Sp Se pi PPV NPV
Corra Modelb Bias RE CP Bias RE CP Bias RE CP Bias RE CP Bias RE CP
0 1 0 1 0.94 0 1 0.93 0.01 1 0.93 0 1 0.94 0 1 0.94
0 2 -0.04 NA 0.52 0.03 NA 0.61 0.19 NA 0.34 0.04 NA 0.84 -0.02 NA 0.75
0 3 0 0.49 0.94 0 0.23 0.94 0.01 1.06 0.95 -0.01 0.76 0.94 0 0.44 0.94
0.5 1 0 1 0.95 0 1 0.94 0 1 0.93 0 1 0.95 0 1 0.95
0.5 2 -0.04 NA 0.5 0.04 NA 0.48 0.15 NA 0.44 0.03 NA 0.91 -0.01 NA 0.9
0.5 3 0 0.5 0.94 0.01 0.28 0.93 0 0.93 0.94 0 0.86 0.96 0 0.48 0.94
0.8 1 0 1 0.94 0 1 0.94 0 1 0.95 0 1 0.96 0 1 0.96
0.8 2 -0.04 NA 0.51 0.04 NA 0.43 0.13 NA 0.46 0.02 NA 0.93 -0.01 NA 0.95
0.8 3 0 0.51 0.93 0.02 0.29 0.92 0 0.81 0.94 0.01 0.85 0.96 0.01 0.48 0.93
aCorr = 0 : (ρεµ, ρεν , ρµν) = (0, 0, 0), Corr = 0.5 : (ρεµ, ρεν , ρµν) = (0.5,−0.5,−0.5), Corr = 0.8 :
(ρεµ, ρεν , ρµν) = (0.8,−0.8,−0.8).
bModel = 1: Hybrid GLMM, Model = 2: Model2, Model = 3: Model3.
Table B.2: Summary of 2000 simulations with data generated from settings with 10
studies and true Se (Sp)=0.7 (0.8).
Sp Se pi PPV NPV
Corra Modelb Bias RE CP Bias RE CP Bias RE CP Bias RE CP Bias RE CP
0 1 -0.01 1 0.94 -0.01 1 0.93 0.01 1 0.93 0 1 0.92 -0.01 1 0.93
0 2 -0.13 NA 0.69 0.09 NA 0.76 0.11 NA 0.82 0.03 NA 0.92 -0.04 NA 0.92
0 3 -0.01 0.49 0.93 0.01 0.35 0.94 0.01 1.05 0.94 0 0.87 0.94 -0.01 0.69 0.94
0.5 1 -0.01 1 0.94 0.01 1 0.94 0.01 1 0.93 0 1 0.95 -0.01 1 0.94
0.5 2 -0.14 NA 0.68 0.11 NA 0.72 0.08 NA 0.88 0.01 NA 0.95 -0.02 NA 0.96
0.5 3 -0.01 0.46 0.94 0.03 0.35 0.94 0.01 0.97 0.94 0 0.9 0.96 0 0.66 0.96
0.8 1 -0.01 1 0.94 0.01 1 0.93 0.01 1 0.96 0 1 0.97 0 1 0.98
0.8 2 -0.14 NA 0.68 0.11 NA 0.7 0.07 NA 0.9 -0.01 NA 0.97 0 NA 0.97
0.8 3 -0.01 0.5 0.95 0.05 0.35 0.93 0.01 0.82 0.95 0.01 0.92 0.98 0.01 0.64 0.97
aCorr = 0 : (ρεµ, ρεν , ρµν) = (0, 0, 0), Corr = 0.5 : (ρεµ, ρεν , ρµν) = (0.5,−0.5,−0.5), Corr = 0.8 :
(ρεµ, ρεν , ρµν) = (0.8,−0.8,−0.8).
bModel = 1: Hybrid GLMM, Model = 2: Model2, Model = 3: Model3.
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Table B.3: Summary of 2000 simulations with data generated from settings with 10
studies and true Se (Sp)=0.9 (0.95).
Sp Se pi PPV NPV
Corra Modelb Bias RE CP Bias RE CP Bias RE CP Bias RE CP Bias RE CP
0 1 0 1 0.93 0 1 0.94 0.01 1 0.92 -0.02 1 0.94 -0.01 1 0.94
0 2 -0.04 NA 0.78 0.03 NA 0.83 0.2 NA 0.63 0.03 NA 0.9 -0.03 NA 0.89
0 3 -0.01 0.46 0.94 0 0.28 0.9 0.01 1.03 0.93 -0.02 0.77 0.94 0 0.53 0.89
0.5 1 0 1 0.93 0 1 0.93 0.01 1 0.93 -0.01 1 0.95 0 1 0.95
0.5 2 -0.04 NA 0.79 0.04 NA 0.78 0.18 NA 0.72 0.03 NA 0.93 -0.02 NA 0.94
0.5 3 0 0.5 0.95 0.02 0.3 0.86 0.01 1 0.95 -0.01 0.86 0.96 0 0.61 0.88
0.8 1 0 1 0.94 0 1 0.95 0.01 1 0.94 0 1 0.98 0 1 0.97
0.8 2 -0.04 NA 0.8 0.04 NA 0.77 0.17 NA 0.74 0.03 NA 0.96 -0.01 NA 0.97
0.8 3 0 0.47 0.95 0.03 0.31 0.86 0.01 0.85 0.94 0.01 0.92 0.99 0.01 0.53 0.88
aCorr = 0 : (ρεµ, ρεν , ρµν) = (0, 0, 0), Corr = 0.5 : (ρεµ, ρεν , ρµν) = (0.5,−0.5,−0.5), Corr = 0.8 :
(ρεµ, ρεν , ρµν) = (0.8,−0.8,−0.8).
bModel = 1: Hybrid GLMM, Model = 2: Model2, Model = 3: Model3.
Appendix C
Glossary for abbreviations
MA-DT: meta-analysis of diagnostic test
NMA-DT: network meta-analysis of diagnosic test
Se: sensitivity
Sp: specificity
NPV: negative predictive value
PPV: positive predictive value
LR+: positive likelihood ratio
LR- negative likelihood ratio
pi: disease prevlaence
AUC: area under the curve
LMM: linear mixed model
GLMM: generalized linear mixed model
MAR: missing at random
MCAR: missing completely at random
MNAR: missing not at random
CI: credible interval
CP: coverage probability
AIC: Akaike informative criteria
MCMC: Markov Chain Monte Carlo
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